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The spread of HIV has been very explosive, mercilessly and remains the most deadly 
disease which has ever hit the planet, since the last three decades. The complexities 
aligned with the spread of the virus have activated this dissertation for a workable 
mathematical model and a suitable treatment interruption.  
Hence, the adopted model is momentous to the government, who is a major 
stakeholder for planning. Further, the study is essential to drug manufactures for 
implementing a workable drug and health workers for designing a suitable treatment 
option for HIV tainted individuals. 
I am highly appreciative and beholden to Professor Emile Franc Doungmo Goufo for 





Comparatively, HIV like most viruses is very minute, unadorned organism which cannot 
reproduce unaided. It remains the most deadly disease which has ever hit the planet 
since the last three decades. The spread of HIV has been very explosive and 
mercilessly on human population. It has tainted over 60 million people, with almost half 
of the human population suffering from AIDS related illnesses and death finally. Recent 
theoretical and computational breakthroughs in delay differential equations declare that, 
delay differential equations are proficient in yielding rich and plausible dynamics with 
reasonable parametric estimates.  
This paper seeks to unveil the niche of delay differential equation in harmonizing low 
HIV viral haul and thereby articulating the adopted model, to delve into structured 
treatment interruptions. Therefore, an ordinary differential equation is schemed  to 
consist of three components such as untainted CD4+ T-cells, tainted CD4+ T-cells (HIV) 
and CTL. A discrete time delay is ushered to the formulated model in order to account 
for vital components, such as intracellular delay and HIV latency which were missing in 
previous works, but have been advocated for future research. It was divested that when 
the reproductive number was less than unity, the disease free equilibrium of the model 
was asymptotically stable. Hence the adopted model with or without the delay 
component articulates less production of virions, as per the decline rate. Therefore 
CD4+ T-cells in the blood remains constant at  𝛿1/𝛿3, hence declining the virions level in 
the blood. As per the adopted model, the best STI practice is intimated for compliance.  
 
Key words: Cytotoxic Lymphocytes; Structured treatment interruption; Disease free 
Equilibrium: Human immunodeficiency virus; Basic reproductive number 
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1.0   INTRODUCTION 
The introduction of the thesis is activated by this chapter and therefore provides an 
insight to the background of the study, statement of the problem, Epidemiological trend 
of HIV in Ghana, mathematical model capable of modelling low HIV viral load, 
objectives aligned with the study, motivation of the study, significance of the study and 
finally the component of the structure of the thesis. 
 
 
1.1     BACKGROUND 
Current mathematical innovations and simulations in delay differential equation, reveals 
that delay differential equations are viable in producing rich and credible dynamics with 
acceptable parameter values. Delay differential equation works on an endless 
dimensional space which accommodates high-dimensional dynamics. The use of such 
mathematical dynamical models [1, 17] to describe a contagion such as the human 
immunodeficiency virus (HIV), became magnified when scientists discovered the 
menace and the threat HIV causes to mankind. AIDS intercepts when the contagion, 
remains untreated for a long period of time. 
 
HIV has been projected to have killed over 25 million people [10], since its first 
recognition from the year 1981 to the year 2005. Significantly, HIV statistics from1999 to 
the year 2010 reveals a major drop of 19% in new HIV infections [20, 21]. However, 
new HIV contagions still remain unacceptably high. Currently about thirty three million 
(33 million) people are still residing with HIV/AIDS [10] and are not even aware of their 
status. Out of such huge infectious rate, 2.5 million of the infected are children. African 
continent alone is indebted with about 68% of the cumulative HIV infection in the world, 




Monitoring the spread of HIV across the world is very arduous and demanding due to 
the risk of being infected, hence key preventive measures are required to inhibit the 
propagation of the disease. Truly, controlling the disease HIV has been more arduous, 
due to the laxity of the methodology [4, 15] used in monitoring the infection and the 
spread of the disease. One of such approaches used to control HIV surveillance is 
basically by informing the public, about some of the new diagnoses of HIV and AIDS 
cases. 
  
Ironically, the contagious rate of the pandemic is irrational and uncompromising, due to 
the huge number of people inclined with the alignment and the reality of a known 
vaccine to eliminate the disease assiduously. However the lives of HIV patients have 
been prolonged through the use of antiretroviral therapy (ART), which has assisted in 
slowing down the pace for the onset of AIDS or other related AIDS sickness. However, 
countries where people have access to ART have shown a realistic decline, on HIV 
death and a pitch in life expectancy [11]. Introduction of therapy has decreased the 
mortality rate [14] and hence by 20% in 2004.  
 Therefore since 1999, the advocacy for a viable treatment interruption has imparted 
roughly on about 14.4 million life-spans [10] on people tainted with HIV/AIDS. 
Further, another means of limiting HIV transmission is marginalized, through total 
behavioral change such as absolute abstinence when not married, or faithfulness to 
one’s partner in the case of married couples. [27] 
Again, improved education and extensive access to condom use for individuals who 
cannot abstain completely from multiple partners, is essential in slumping down recent 
HIV attacks. [28] 
 
However the unmatchable pinnacle of recent HIV infections has articulated an in-depth 
analysis relating to the use of the delay differential equation, to model low HIV viral 
state. The study further investigates the viral load of an infected individual and the need 
to ascertain when a particular therapy should be modified, continued or discontinued, 
due to drug-resistive modifications (DRMs) [52]. Drug resistive viruses, resides on a 
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particular drug type and regenerates its kind unnoticed, even when therapy is still 
ongoing [102, 104]. 
 
 
1.2   STATEMENT OF THE PROBLEM 
Authentically, credible approaches to managing and mortifying the negative effects of 
any infectious disease, are aligned with a better comprehension of the nature and the 
mode of transmission of such disease. Tremendous and exciting researches are 
ongoing to unlock the treat caused by HIV/AIDS and also to stipulate a perpetual 
solution to the disease. These researches are underlined to underscore an in-depth 
comprehension of the disease at cellular level, by means of mathematical models. The 
incorporation of such mathematical models stimulates the advancement, or changes 
associated with a particular drug type and its administration [70]. HIV-1 has since been 
known to be the most hazardous virus, which after infection, focuses on the CD4+ T 
cells and ascertain access for its existence and continual replication. Per the infection of 
HIV-1 virus, the immune system is breached, resulting to lots of opportunistic diseases 
which are beyond the control and administration of the body’s immune system.  
 
The use of delay differential equation assists, by comparing the infected group of cells 
[6] with the uninfected cells, in relation to the time interval stipulated for such infection. 
Hence mathematical models, such as delay differential equations are key and vital in 
modelling the spread of HIV/AIDS, due to its associated time component. Most 
legitimate approaches have time delays embedded in them, but handfuls of researchers 
are able to model infectious diseases with time lags. However, the intricacies of time 
delays are associated with challenges ascribed to the layout of the model and the 
urgency to unlock and stabilize the unit, through dimensional analysis [125, 132].  
 
In accordance to the above, most scientists [1, 2, 6, 7, 11] have therefore developed 
SIR models to include time lags. The time lags are designated for the arduous 
parameters in the model and their associated biological meanings. In relation to the 
above [13], a delayed model has been established to explain the standard mass 
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interaction and the universal soundness of the model. Again an SIR model which 
incorporates time delay was studied [12] for an infected state, to ascertain the 
significance of time lags in an SIR model. The resulting model was stabilized through 
Hopf bifurcation and hence supported the repercussions of the delay component. 
Further studies on SIR models [11] revealed the essence of stability and the heroics of 
density parameter in accounting for low HIV viral haul.  
 
In congruence to the above problem and the need to find an amicable solution, this 
study designs an ordinary differential equation, composed of untainted CD4+ T-cells, 
tainted CD4+ T-cells and cytotoxic lymphocytes. The delay element is introduced in 
accordance to the formulated model, to enhance intracellular delay and HIV latency 
which were missing in previous works, but have been recommended for further 
research. The study further uses the stability of the developed DDE model to delve into 




1.3     EPIDEMIOLOGICAL TREND OF HIV IN GHANA 
Ghana's HIV prevalence rate has stabilised over the last five years, starting from the 
year 2014 through to the year 2020. A study conducted recently by Abigail et al (2019) 
intimated that about 334,714 people are currently tainted and residing with the virus, as 
well as 19,931 new mortality rate of infection. The study further intimates, that Greater 
Accra Region is recently on the pinnacle of infection with about 77,132 people tainted 
by the virus. Hence, per the number of tainted people, about 28,000 are currently 
adhering to ART, whilst 3,000 people have passed on. However, the country has 
recorded declines in the prevalence rate among key populations, such as the youth, 
pregnant women, children and the adult populace. Again, significant reductions have 
been realized in new contagions. 
 Again, according to Angela E.D (2015), an estimate of 235,982 people were living with 
the virus, together with 27,734 tainted children, representing 11.8 percent of the 
estimated figure.  
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Further, in 2016 [49], a national HIV Prevalence rate was conducted and revealed that 
about 13%, of the people are currently tainted with the disease, representing an 
estimate of 224,488. Out of the infected figures, 34,557 were adults and 18000 were 
children. 
 
Again, additional review was conducted in 2017 [21] and intimated that 10,074 people 
passed away due to AIDS progression and other related disease [23]. Among those 
who died, 2,248 were children between the ages of 0-14 years whilst 7,826 were adults. 
However, life expectancy and HIV progression to AIDS could be delayed when ART is 
available for treatment options.  
Notwithstanding, the national HIV Prevalence rate in 2018 also proclaimed that the 
percentage of pregnant women tainted by the virus and attending antenatal clinic were 
1.9%, which portrays a decrease of 2.1% in 2017. The regional HIV prevalence from the 
northern region up to the southern region was 19.7%. Eastern region [23] has the lion’s 
share of the menace, compared to the least infectious rate of 6.0% from the Northern 
and upper west part of the country.  
 
Finally, Abigail et al (2020) also conducted a regional HIV prevalence study to reveal 
the spread and impact of the disease on regional basis. As per the study about 334,714 
people are currently tainted and residing with the virus, with 19,931 new mortality rate of 
infection. They lamented further that, Greater Accra Region is recently on the pinnacle 
of the infection with about 77,132 people tainted by the virus. Hence, as per the number 
of tainted people, about 28,000 of them are currently adhering to the use of ART whilst 
3,000 people have passed on. It was argued that the second most tainted HIV region 
was Ashanti region, with a peak infectious rate of 75,675. The percentage regional 
statistics in descending order stands as follows: Greater Accra Region 23.04%, Ashanti 
Region 22.6%, Eastern Region 20.8%, Western Region 17.6 % Brong Ahafo Region 
17%, Upper East Region 10.2%, Volta Region 9.8%, Central Region 9.2%, Northern 
Region 6.9%, and Upper West Region 6.9%. The prevalence of HIV according to type, 
also stands as follows: HIV Type one 97.1%, HIV Type two 0.8% and combination of 
HIV Type one and two 2.1%.  
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1.4     NOTES ON MATHEMATICAL MODELLING OF HIV  
Modelling of epidemic diseases using mathematical concepts has not only broadened 
our knowledge on HIV over the last decade, but has also provided answers and clues to 
areas of the pandemic that has not been explored. It has also helped in providing a 
genuine umbrella for drug induced viral suppression, evolved from a meaningful ART 
usage. Several researchers have invented stochastic and deterministic models [8, 10], 
which have imparted positively in curbing down the viral growth of the virus and 
tremendously improved drug therapy. 
 It’s fair to acknowledge that (ODEs) have been significant in the cross examination of 
valuable cells, such as tainted and untainted cells. The study takes a look at ODE 
model which is later transformed to DDE model. Hence, the developed model is 
schemed of CD4+ T cells, tainted CD4+ T cells and Cytotoxic-T-lymphocytes (CTLs). 
Further, the extremes associated with ODE models as eluded by previous researches, 
were accounted for and modified to include intracellular delay. The inclusion of the 
delay unit explains the interval essential for a cell to navigate before the propagation of 
virions.  
Therefore per the achievement of the stipulated aim of the study, a non-continuous time 
delay(𝜏) is mooted to the formulated model, to mediate for vital components between 
the period of a contagion and the production of viral particle. Arguably, the incorporation 
of the time delay (𝜏) was first initiated by Herz et al. The necessity of this component 
was further highlighted by Nelson and Perelson. They intimated the essence of 
intracellular in viral production, when drug efficacy is fragile [124]. In addition, cytotoxic 
Lymphocytes have been extended to the parameters to account for immunological 
response. CTLs contribute immensely by attacking and killing infected cells in the blood. 
The activities of CTL are sparked by CD4+T cells through simulations, which results in 
the production of antibodies to combat the virus invasion in the blood. However CTL’S 
are known to have a protein called CD8, which are embedded on their surface. They 
are able to attach themselves to other molecules as a result of a receptor, which has the 
capacity of perceiving antigens produced by infected cells. CTL kills infected cells 




 The process of mathematical modelling orients on the complexity and evidence of 
clinical data obtained from patients infected with the Virus; hence due to the ambitions 
of the study, limited treatment transitions data was used to validate the model. 
 
 
1.5   RESEARCH AIMS AND OBJECTIVES  
This section deals with the questions which arose in the course of the research, as well 
as the objectives of the study. 
 
 
1.5.1 RESEARCH QUESTIONS 
The study uses the application of delay differential equation, to model low HIV viral load 
in a country like Ghana. In the course of applying the model, the following questions 
resulted thereof:  
 What effects have strong CTL on low HIV viral load? 
 What effects have the delay and non – delay component on viral production? 
 What is the role of a delay model on low HIV viral load? 
 What effects has Hopf bifurcation on the stability of the model? 
 What are the impacts of the model on STI systems? 




1.5.2    OBJECTIVES OF THE STUDY 
In pursuit of the questions arriving from the study and the need to unlock such ideas, 
the following objectives have resulted thereof: 
 
 To ascertain the effects of delay differential model on low HIV viral haul 
 To verify the impact of delay and non-delay component on viral production in the blood 
 To verify the conditions for the existence of Hopf bifurcation and the stability of the 
model   
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 To apply the adopted model to delve into structured treatment interruptions 
 To identify the challenges associated with STI and suggest the way forward 
 To address the limitations associated with ODE model 
 To transform the ordinary differential model to delay differential model. 
 To verify  the effects of the reproduction number on the production of virions  
 
 
1.6    MOTIVATION OF THE STUDY 
The introduction of effective ART to HIV patients to eradicate the contagion, has 
contributed a lot to improving the life expectancy of people diagnosed with the disease. 
Studies have revealed [9] that, the administration of antiretroviral therapy (ART) in 1996 
has approximately added 14.4 million years to people who have contracted the virus. 
However the unmatchable speed at which recent infections are diagnosed and the 
speed at which the disease is spreading has culminated an in-depth analysis to the 
spread of HIV/AID.  Hence by this study, delay differential equation is adhered to model 
low HIV viral load and the adopted model, applied to therapy interruptions. The following 
have been the epitome, or the motivation for using delay differential equation for the 
study: 
 
 To find out the impact of ordinary differential equation in modelling low HIV viral load 
 To identify the deficiencies associated with the ordinary differential equation model and 
the need to introduce the delay component 
 To find out the effect of a strong cytotoxic- lymphocytes (CTL) on a low HIV viral load  
  To verify the influence of infected CD4+TCells, the uninfected CD4+TCells and CTL 
when the reproductive number is kept constant 
 To verify the impact of delay and non-delay on viral production in the blood 
 To uphold the existence of Hopf bifurcation and the stability of the model   






1.7     SIGNIFICANCE OF THE STUDY 
Ideally, the study will have direct influence on the following stakeholders: 
 
 A major and key stakeholder such as the government has been battling, to find a lasting 
remedy to HIV/AIDS which has direct bearing on the productivity of a country. The effect 
of HIV/AIDS is replicated in all the agencies within a country namely; health, education, 
services and so on. Therefore the outcome of this study will provide the needed 
knowledge on treatment options, required to improve life expectancy of the disease. 
Further the stability of the developed DDE model will be used to design a potential 
structured treatment interruption for future testing of the disease.  
 
 The use of medication to curtail the virus is essential to HIV tainted individuals; however 
the virus develops resistance over time to a particular drug type. Therefore, this study 
has a significant contribution to manufacturers of drugs, by exposing them to knowledge 
on modifying, continuing or discontinuing a particular drug type due to drug-resistant 
mutations. Drug manufacturers through the recommendations of the study will now have 
the luxury of manufacturing drugs, which have the potency to resist mutations from 
virus. Drugs could then be produced with at least 100% efficacy. 
 
 The results are also key to health personnel’s and other health organizations, in    
designing a potential structured treatment interruption for future testing of HIV/AIDS and 
a more virulent treatment options to infected individuals 
 
 The infected public could also benefit from a prolonged life expectancy of HIV/AIDS on 
the recommendations, relating to the design of a proper potential structured treatment 
interruption, as well as the administration of drugs which are 100% efficient  
 
 
1.8    STRUCTURE OF THE THESIS 
Provisionally, the thesis has been planned and divided into five chapters which are 
concealed in each other. The chapters are developed to provide the needed information 
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which is capable of formulating the ordinary differential model, as well as the 
transformation required for the ODE model to delay differential model. The attained 
DDE is used for modeling low HIV viral load as well as treatment options. 
  
The chapters are developed in the following order: 
Chapter 1 provides an insight into the introduction of the thesis and therefore deals with 
the background of the study, statement of the problem, Epidemiological trend of HIV in 
Ghana, the mathematical model capable of modelling low HIV Viral load, objectives of 
the study, motivation for the study, significance of the study and finally the component of 
the structure of the thesis. 
 
Chapter 2 explains the general background pertaining to HIV/AIDS, including HIV 
transmission and how it can be controlled. Further, the chapter also builds up the 
biological background of the pandemic and how to develop deterministic ODE models 
and the need to transform it to intracellular delay differential equation 
 
Chapter 3 addresses modelling in terms of in-vivo, in-vitro and in-silico analysis. Again, 
the chapter talks about the development of Pre-deterministic modelling, single target 
cell modelling and multiple target model. This is followed by doubling- time and half-life, 
as well as modelling multiple target cell model with chronic infection and intracellular 
delay 
  
Chapter 4 is interlocked with the analysis of the model with delay, well posedness and 
existence of equilibrium points. Further consideration is given to the global stability of 
equilibrium and the endemic equilibrium. Application and proof of existence of Hopf 
Bifurcation are simulated by this chapter and hence the numerical simulations of the 
results are considered for discussion. The chapter finally assesses the repercussions of 





Chapter 5 deals with the general overview of the study and the summary of findings. 
The chapter is further interlocked with the future directions to researchers and the 
































INCEPTION AND DEVELOPMENT OF HIV 
 
2.0   INTRODUCTION 
This chapter explains the general background pertaining to HIV/AIDS, including HIV 
transmission and how this can be controlled. Further, the chapter also builds up the 
biological background of this deadly disease and how to develop deterministic ODE 
model for further transformation to delay differential equation. 
 
2.1   GENERAL BACKGROUND OF HIV/AIDS  
HIV/AIDS can be referenced as early as the year 1920 when the initial infection was 
mooted through the blood samples of a man from Kinshasa, in the republic of Congo. 
Genetic analysis revealed that, the initial contact with the virus might have pranged in 
the late 1940s or 1950’s. A similar analysis also revealed the existence of HIV-2 in 
humans which is less infectious than HIV-1[16, 63]. 
 
2.1.1   TRANSMISSION OF HIV-1 
Earlier, scientist sourced that HIV-1 emanated from a peculiar blend of Chimpanzee in 
West Africa to humans. The assertion was that the Chimpanzee version of SIV was 
ushered to humans in the form of HIV-1, through blood affiliation, when those 
chimpanzees were hunted for meat (bush meat trading). Through the advancement of 
blood affiliation, the virus was propagated to Africa and the entire world at large. 
Scientist came with a generalized conclusion based on their findings that HIV-1 
emanated from Chimpanzees. Secondly blood affiliation between chimps and humans 
articulated the transfer of the virus to humans. HIV and SIV share similar 
characteristics, therefore both diseases attack the immune systems of human beings, 
monkeys and apes respectively. HIV and SIV are both a lentivirus which attacks the 




2.1.2      TRANSMISSION OF HIV-2 
It is remarkable to articulate that HIV-2 was transmitted to humans through SIV in sooty 
mangabey, associated in monkeys rather than chimpanzees. The initial contagion of 
HIV-2 to humans was activated by the same process, which initiated the contagion of 
HIV-1.  Interestingly HIV-1 is more dangerous and highly contagious compared to HIV-
2, however HIV-2 is commonly associated with people residing in countries such as 
West Africa, particularly in Mali, Nigeria and Sierra Leone. 
Further, it is worth noting that the two different strains of SIV from monkeys and apes, 
as discussed above merged to reproduce a third virus called SIVcpz. This third 
discovered virus was also transferred to humans through direct blood affiliation, which 
emanated from the killing and eating of the Chimpanzee. 
Genetically there exist four main types or groups of strains such as M, N, O and P, with 
slight differences in their composition. It’s worth noting that the virus replicates in 
different strains in humans, hence making it arduous to combat the disease. The virus 
has the propensity to produce different types of strains of HIV-1 in an individual. The 
main types or groups of strains are further broken down into a number of sub-groups 
[36].  Arguably 90% of HIV-1 infection is attributed to the M strain of the virus, which has 
further division of strains such as A, B, C, D, F, G, H, J and K 
(http://en.wikipedia.org/wiki/File. :HIV-1 subtype prevalence 2002.). Realistically each 
strain of the virus is basically associated to a specific geographical area. It is hoped that 
the knowledge relating to the strains and the geographical areas, will enhance planning 
of successful treatment options. It is however relevant to reverence the necessity of a 
cross-subtype contagion, which enhances the advancement of a fresh breed of virus 
[15]. The production of new breed of viruses as a result of cross contagion between viral 
strains is referenced as CRFs (circulating recombinant forms). CRF’s has pivoted the 
combat of the virus to an arduous level, due to its ability to propagate several viral 
strains which are resistive to treatment options. This explains why many treatment 
options have failed in the pass and hence the need to integrate two or more ARV’s to 
combat the disease [37]. Therefore the success to any treatment option is linked with 
the knowledge about the viral haul, as well as the type of viral strain responsible for the 
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contagion. Ideally as per the above assertion, it’s essential to promote suitable and 
accessible HIV testing to all the people residing in a particular locality. This implies that 
for any successful treatment option and the combat of viral mutation, individuals should 
be encouraged to ascertain their viral haul and strain as well. 
Finally as per the above discovery, it is suggested [30, 38] that HIV-1 evolved from 
primates. It is confided that the Sooty Mangabey monkey resident in sub- Saharan 
Africa, is responsible for the transmission of HIV-1. The inception of the virus is 
attributed to the trade-off between humans and monkeys, when such monkeys were 
killed and hunted for as food [30, 39]. On the other hand, Primates are host to SIV, yet 
they are able to impede the spread of the virus. This is due to its robust immunity which 
impedes the intercession of the virus as per humans which leads to AIDS [40]. The 
mechanism associated with the robustness of the immunity of primates and for that 
matter moneys, could be associated with the long term persistence of their immune 
system [30]. This special attributes of primates immune system cannot be said of 
humans, who advances to AIDS in the course of time and death finally.    
 
 
2.2      BIOLOGICAL BACKGROUND OF HIV AIDS 
Basically AIDS is an ailment portrayed by the dynamic weakening of a patient's resistive 
framework. This immunological weakness permits irresistible viruses, in the form of 
bacteria and parasites to attack the body and engender their kind rapidly. The 
occurrences of specific tumors are significant on HIV tainted patients, as a result of the 
weakened resistive framework. Therefore the contagion propagates death in the 
soonest of time. 
 
The thump against the HIV plague has brought forth logical and exceptional 
methodologies relevant to combat the disease or suppress it amicably. The zeal to 
suppress the contagion has articulated a blend of clinical research, atomic science, 
immunology and mathematical sciences to combat the disease. Essentially, the virus 
has an exceptionally high transformation rate, which enables the virus to produce 
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several strains within the shortest possible time.  This high change rate permits HIV to 
effectively develop protection from drugs and hence very arduous to stimulate an 
antidote for the disease.  The tenacity of the virus in the human body is also attributed 
to its ability to adhere to latency for a period of time, before initiating an infection. In this 
way, the advancement of medications and antibodies depends not just on information 
on the arduous life pattern of the virus, but also understanding the complicated resistive 
system of the body. Ideally so, HIV suppressing requires more than the advancement of 
medications and antibodies, but a better understanding of the virus, in order to inhibit 
the production of different strains of viruses within an individual.  
 
 
2.2.1   THE IMMUNE SYSTEM 
Essentially, the human body has the ability to initiate both vague and explicit means of 
militating against the virus, hence understanding the different segments of the human 
resistive framework is vital to the thump against HIV. Vague defence system in the body 
functions rapidly and unpredictably to eliminate organisms in the body. Some of the 
vague defence systems in the body include the following: bodily fluid, gastric juice hairs, 
and cilia in the respiratory tract etc. This vague defence system sincerely prevents the 
entry of harmful organisms into the body. 
 
The human body has been programmed to respond voluntarily to the occurrence of 
certain complex situations, such as initiation of fever and inflammation to seduce 
pathogens in the body. Noticeable among the vague defence system is the phagocytes, 
a specific kind of leukocyte (white platelet), which has the ability to circulate and destroy 
different viruses as well as residue and dust. In the event where the phagocytes are 
breached and penetrated, the leukocytes mount coordinated protections against the 
explicit intruders.  
 
Conversely, an unsuccessful attack by the Lymphocytes triggers a further back up for 
the entire process. In the process of activating a successful response to the viral attack, 
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the B cell of lymphocytes develops into counter acting agent which terminates the 
intruder. Similarly, T cells also incorporate some amount of safety by legitimately 
eliminating tainted cells. The remaining T cells functions administratively by discharging 
signals worthy of invigorating the blood to function efficiently in the defence process. 
Unfortunately HIV specially contaminates one of the administrative functions of the T 
cells, specifically the T helper cells and subverts the body’s resistive frame work 
prompting AIDS.  
 
   
2.2.2    THE CENTRAL ROLE OF HELPER T CELL 
It’s worth noting that the organization and defensive mechanism of the body’s resistive 
system are harmonized by the T helper cells. They discharge chemical information 
called (cytokines), which activates the vague resistive system of the body to proceed 
with reinforcement and support for the other cells.  Basically Helper T cells coordinate 
the entire activities of the body’s resistive system. Therefore they are termed as 
directors of the body’s resistive system. Additionally they are also known as the 
"officers" of the body’s resistive framework, because of their organizational role.  
 
They are also responsible for organizing the other cells in the blood to fight and defend 
the body whenever a virus invades (figure 2.1). In the event of an invasion by a foreign 
particle, it is the sole responsibility of the T helper cells, to call upon other cells such as 
B cells, cytotoxic T cells, and other helper T cells to wrestle against such attacking 
pathogens (figure 2.1). Figure 2.1 depicts a specialized Macrophage cell which shows, 








Fig 2.1 (Specialized Macrophage cell which ingest foreign antigens invading the host 
cell) 
As per figure 2.1 above, when the cell’s defence system is breached by the entrance of 
a virus, Macrophage cells articulate the information immediately to the T Helper cells to 
action it. Macrophage cell is a phagocytic cell, hence is able to encircle the unwanted 
bacteria, or virus, which has had entrance to the cell and destroys it completely. 
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Implanted inside the macrophage cell layer, is a particle created by the blood cells 
called human leukocyte antigen (HLA) complex. The HLA functions by assisting the 
Helper cells and antigen to be attached to it. However, Helper T cells which have 
receptors are able to link up with the antigen and get attached to the macrophage. 
When the cells are bounded together, the helper T cells multiply and advance to a clone 
of cells, equipped for perceiving a similar antigen. Again with reference to figure 2.1, the 
obtained T clone cells are known as the commanders of the cell, due to their specified 
roles. The T Clone cells function by producing chemical signals which instigate the cells 
to embattle any unwanted particle in the blood. 
 
Additionally, T cells supports the body’s defence system by invigorating cytotoxic T cells 
(TC), to eradicate cells that have been tainted by the HIV virus. Hence, there are 
antigens on the surface of the cell; which repairs the surface discarded by the tainted 
cells. The antigens are explicit to the culpable specialist, and hence link the receptors in 
the layers of the particular TC cell.  
 
Moreover, TC cell attaches itself to the MHC atom from the outside of the tainted cell. 
Hence when TC cells are is limited by the antigen outside the HLA particle, the cytotoxic 
T cell releases a substance called "perforin," which wrecks the culpable cell (figure 2.2). 
The helper T cell likewise animates the creation of antibodies and also produces clues 
which invigorate the creation of B cells. The created B cells separate into plasma cells 
and the plasma cells are platforms responsible for the creation of antibodies. The 
antibodies are used to explicitly combat pathogens flowing in the blood or lymph. 
Antibodies work by hindering the receptors that permit pathogens to be connected to 
target cells, or by making holes on microscopic organisms. The sole duty of phagocytes 
is to encircle viruses and hence eliminated them. The phagocytes promptly encircle the 
invaded microbes in the blood. They are strengthened by the presence of opsonins, 
which are produced from jointed antibodies.  
 
 Further, it also advocated that antibodies [18] could activate a course of biochemical 
responses, which destroys the membrane of any invading cell. Therefore the 
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significance of the human resistive system depends on the helper T cells. A healthy T 
cells leads to the formation of a strong immune system and a tainted T cell, destroys the 
immune system completely. Surprisingly HIV targets the T cells and renders it useless, 
resulting to a low viral haul. Therefore, the advancement of HIV contagion disintegrates 




Fig 2.2 (Binding of  antigens and Macrophage molecule which initiates secretion 
of lytic cells) 
 
 
2.2.3    THE STRUCTURE AND LIFE CYCLE OF HIV  
Comparatively, HIV like most viruses is very minute, unadorned organism which cannot 
reproduce unaided. It remains the most deadly disease which has ever hit the planet 
since the last three decades. The spread of HIV has been very explosive and 
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mercilessly on human population, tainting over 60 million people, with almost half of the 
human population suffering from AIDS related illnesses and death finally. Therefore a 
comprehension of the structure and life pattern of the contagion is critical in planning 
viable treatment systems. HIV is encompassed RNA infection which propagates from 
the host cell during replication.  The replicate develops phospholipid envelope which 
has peg-like structures and allows the viral RNA to code itself. The pegs comprises of 
three or four glycoproteins (gp41 stem), which are embedded with three or four 
glycoproteins (gp120). Again within the envelope is the shot molded nucleocapsid which 
is manufactured from protein and encircled by two single strands of RNA. (Fig 2.3). 
 
 
Figure 2.3 (Binding of HIV to the host cell using Gp20 of the virus to the CD4+T cells) 
 
In spite of the fact that helper T cells appear to be the principal focus for HIV, different 
cells can get tainted too. Other cells which could get tainted include monocytes and 
macrophages which can hold huge quantities of infections within and without being 
destroyed. It is ascertained that some T cells harbors comparative repositories of 
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infections, which lie latent for a long period of time. The latent viruses are rekindled 
when the pool of virus has been eradicated by therapy.  Since viruses are particles and 
only requires a host cell to become active, it takes support from one of the gp120 atoms 
in order to taint the CD4 particles on the host cell's surface.  
 
However, for the virus to attach itself to the host cell, it requires two processes to get 
itself attached to the host cell. In the initial stages it adheres to CCR5 which is a 
chemokine receptor and provides support for the virus within the initial stages of the 
contagion. The virus finally gets the second support from chemokine receptor (CXCR4) 
during the later phase of the infection. Therefore during the asymptomatic stage of the 
infection, latent virus rekindles the infection on the macrophages and taints them 
amicably. This explains why a tainted individual appears to be healthy in the 
symptomatic stage of the infection. The signal for the contamination of the virus is not 
visible and hence integrates in numbers. This unseen process eventually destroys the 
human resistive system and integrates to AIDS in the course of time.   
 
HIV has a novel life cycle and belongs to the group of retroviruses (fig. 2.4).  When HIV 
ties to a host cell, the viral envelope wires with the cell layer, and the infection's RNA 
and chemicals enter the cytoplasm of the host cell. The virus activates its infection by 
making use of its reverse transcriptase which is a single stranded RNA. The single 
stranded RNA is used as a tool to duplicate the two folded DNA of the host cell.  The 
chemical integrase in the RNA encourages the reconciliation of the viral DNA with the 
host cell’s chromosome. The virus’s DNA called Provirus is repeated alongside the 
chromosome of the host cell when the cell isolates. The coordination of provirus into the 
host DNA empowers the virus to replicate the host cell successfully. Therefore viral 
protein is created when the provirus is translated as per the successful replication of the 
virus. Viral proteins are then collected and this time, the virus utilizes the host cell's 
protein copy for the production of its kind. The virus's protease then articulates the 
manufacture of proteins by converting polypeptides to proteins and hence propagates 




As per the above, the life cycle of the virus reaches its fruition stage; hence the virus 
inevitably buds out of the cell and starts a new contagion. Many viral particles continue 
to bud out of the tainted cell through its life span until the tainted cell is completely 
destroyed. Further, it should be noted that a tainted cell continues to be a host and a 
hide out for the virus once it has been budded by the RNA of the virus (figure 2.4). 
Figure 2.4 depicts how the virus binds with the host cell, fuses its self to the host cell's 
chromosome and propagates out of the host cell, to begin new infections. 
 
  
Figure 2.4 (Binding and budding of viral particle from a host cell) 
 
As per figure 2.4, the following are the processes which  take place in the binding and 
budding of a viral particle on a host cell: 
Stage 1: The viral RNA and reverse transcriptase proceed to the cytoplasm of the host 
cell as per the budding of the virus and the host cell. 
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Stage 2: Reverse transcriptase mediates the process of integrating the viral RNA to the 
host cell’s DNA 
Stage 3: The budding process of the Viral DNA to the host cell yields a provirus 
Stage 4: Transcription and translation process 




2.2.4    THE TRANSMISSION OF HIV 
HIV is propagated primarily via several forms, but noticeable among the forms of 
transmission include sexual contact, blood and its product and maternal transmission 
during birth. Per the above mentioned, includes homosexuals who contribute 
significantly to the spread of the virus, as they disregard all precautionary measures 
related to their safety. In addition to homosexuals, lie drug users who are extensive 
contributors to the spread of the virus. It is of value to note that some of the drugs 
utilized by drug users cannot be assimilated directly, hence the need to inject the drug 
through a needle into the body.   
 
Further, it is revealed [18, 19] that about 13% to 35% of tainted pregnant women are 
likely to pass on the disease to their infants. The transmission of the virus is articulated 
in the uterus and effected during birth. In addition, Breast milk from such tainted 
mothers also enhances the spread of the virus.   
Finally, it is worth to note that the saliva of an HIV tainted individual contains little 
amount of the virus, however is not possible for kissing to instigate the spread of the 







2.2.5     PROGRESSION OF HIV INFECTION  
Realistically HIV has a long latency stage where the virus advances to AIDS.  The 
period between the initial contamination and the inception of AIDS is between eight to 
ten years on the average. The time frame for HIV inception could be more or less 
depending on the immune system of the individual concerned. Consider the basketball 
player Magic Johnson who happens to be moderately sound, twelve years after he was 
reported of the virus. However not all tainted individuals or cases shows such a long 
time frame, whilst some tainted individuals spend less amount of years before the 
inception of AIDS. 
 
Basically the inception of AIDS or the spread at which the ailment advances is 
influenced by numerous components, such as hereditary or underlying conditions of the 
individual. A critical study of the nature of HIV by the Center for Disease Control and 
Prevention (CDC) has recognized phases for HIV contamination. The phases are based 
on the symptoms one exhibit, when tainted by the virus in the initial stages. The 
categories are A, B, and C and are vital, since it is sometimes arduous to visualize 
some of the symptoms in a tainted individual.  A look at individuals specified in category 
(A), reveals mononucleosis-like ailment such as cerebral pain, muscle hurt, sore throat, 
fever, swollen lymph nodes and headache. However a real and reliable confirmation to 
this deadly ailment is through blood test, since most of the people in this category are 
asymptomatic within the first three weeks of the contagion.  
 
However, irrespective of each stage or classification of the symptoms, the inception of 
AIDS is projected by the development of a rash. Even though the occurrence of rash 
may help separate this disease from other different contaminations, it may not be 







2.3    DEVELOPMENT OF DETERMINISTIC ODE MODELS AND TRANSFORMATION 
 
Modelling of epidemic diseases using mathematical concepts has not only broadened 
our knowledge on HIV over the last decade, but has also provided answers and clues to 
areas of the pandemic that has not been explored. It has also helped in crafting reliable 
treatment options, which has been helpful to HIV tainted individuals. Several 
researchers [27, 36] have invented stochastic and deterministic models, which have 
imparted positively to the control of the virus and slowing down the inception of AIDS. 
Again such models have broadened the knowledge based of the effects of the virus on 
therapy options [24, 25]. 
 Ideally most of the deterministic models use Ordinary Differential Equations (ODE) to 
specify variations aligned with key cells of the model, such as target cells, tainted cells 
and virus level. The use of ODE models by previous researchers has been modified due 
to recommendations to include intracellular delay [135]. The inclusion of the delay 
component explains the duration specified for a cell to become tainted and produces 
virions. The inclusion of the delay component yields DDE, which has been activated for 
the study. 
  
The rationale behind the study is to model low HIV viral haul of an infected state, using 
delay differential equation and hence use the resulting equation on therapy 
interruptions. Therefore, the developed model will be used to ascertain when a specified 
therapy [162] should be modified, continued or stopped and under what circumstances. 
Notwithstanding, the adopted model will further be adhered to structured treatment 
interruptions (STIs) and adoption for compliance. 
 
The process of mathematical modelling is the art of articulating abstract situations 
[151,152, 153], such as HIV infection rate to real and marginable situation. Therefore in 
an attempt to marginalize the reality of the developed model, an STI data is used. The 
STI data generally occurs infrequently. Finally the validly and efficacy of the developed 




2.3.1   ORDINARY DIFFERENTIAL EQUATION (ODE) 
In accordance with the development of a differential equation which is later transformed 
to a delay model, an ODE model is first formed from routine and restricted HIV data [42, 
137]. The model is defined to include CD4+ T cells, tainted CD4+ T cells and Cytotoxic-
T-lymphocytes cells (CTLs). Further, T, V and C are outlined respectively as the 
population compactness of CD4+ T cells, tainted CD4+ T cells and CTLs respectively at 
time (t). 
First we express the population parameters T, V and C as a system of ordinary 
differential equation with respect to time as shown below: 
                                                       
𝑑𝑇
𝑑𝑡
= 𝛿1 − 𝛿2𝑉𝑇 − 𝛿3𝑇  
                                                       
𝑑𝑉
𝑑𝑡
= 𝛿4𝑉𝑇 − 𝛿5𝑉 − 𝛿6𝑉𝐶  
                                                       
𝑑𝐶
𝑑𝑡
= 𝛿7𝑉 − 𝛿8𝐶                                        (2.1) 
  
 
From equation (2..1),  𝛿1 represents the output rate of CD4+ T cells, (𝛿2), represents the 
death rate of CD4+Tcells due to the contagion, (𝛿3), represents the normal death rate of 
CD4+ T cells, (𝛿4), represents the output rate of the virus, (𝛿5), represents the death 
rate of a virus, (𝛿7) represents the carbon copy of CTL, (𝛿8) represents the natural 
death of CTLs, whilst 𝛿6𝑉𝐶 represents the reduction of the infective virus. 
 
 Now consider the introduction of new parameters and new variables to equation 2.1, 
where: 
 𝑎1 = 𝛿3,     𝑎2 = 𝛿5,   𝑎3 =
𝛿1𝛿4
𝛿3𝛿5
 ,    𝑎4 =
𝛿3𝛿6𝛿7
𝛿2𝛿8
,    𝑎5 =  𝛿8      and                               
     𝑥 =
𝛿3
𝛿1
𝑇,    𝑦 =  
𝛿2
𝛿3
𝑉 ,    𝑧 =
𝛿2𝛿8
𝛿3𝛿7
                                                                   (2.2) 
The parameters 𝑎1 𝑎𝑛𝑑 𝑎4, denotes the fundamental reproductive ratio and the death 
rate of the virus respectively. Therefore writing the equations in terms of x, y, and z   
where CD4+T-cell is symbolized as  (x), tainted HIV cell symbolized as (y) and CTL,  
symbolized as (z). The equation can be written as follows: 
                                                       
𝑑𝑥
𝑑𝑡
= 𝑎1(1 − 𝑥𝑦 − 𝑥) 
27 
 
                                                       
𝑑𝑦
𝑑𝑡
= 𝑎2(𝑎3𝑥𝑦 − 𝑦) − 𝑎4𝑦𝑧                          (2.3) 
                                                        
𝑑𝑧
𝑑𝑡
= 𝑎5(𝑦 − 𝑧)                                               
 
We now define three non-linear functions as follows:   
𝑓(𝑥, 𝑦, 𝑧) = 𝑎1(1 − 𝑥𝑦 − 𝑥),     𝑔(𝑥, 𝑦, 𝑧) = 𝑎2(𝑎3𝑥𝑦 − 𝑦) − 𝑎4𝑦𝑧,    ℎ(𝑥, 𝑦, 𝑧) = 𝑎2(𝑦 − 𝑧) 
                                                                                                                          (2.4) 
The three non-linear functions above are differentiated to produce equation (2.5) below:  
                           
𝑑𝑥
𝑑𝑡
= 𝑓(𝑥, 𝑦, 𝑧),       
𝑑𝑦
𝑑𝑡
= 𝑔(𝑥, 𝑦, 𝑧),         
𝑑𝑧
𝑑𝑡
= ℎ(𝑥, 𝑦, 𝑧)                 (2.5) 
 
We further define a point (𝑥, 𝑦, 𝑧̅ ) for equation (2.5) and initialize it as follows:  
 
 𝑓(𝑥 , 𝑦, ?̅?) = 0,     𝑔(𝑥,  𝑦, 𝑧̅) = 0,      ℎ(𝑥 , 𝑦, 𝑧̅) = 0                                                       (2.6) 
 
 
Proposition   2.1   
Now, if we expound the parameters 𝑎2, 𝑎3, 𝑎4 from equation 2.3, as 𝑎2, 𝑎3, 𝑎4 > 0 then, 
the following holds: 
 (i)  if 𝑎3 ≤ 1, a non-negativity steady state exist for equation (2.3), where               
(?̅?𝑜 , ?̅?𝑜, 𝑧?̅?) = (1,0,0)                                                                                                  (2.7)                                                        
(ii) if 𝑎3 > 1, then the non-negativity steady state for equation ( 2.3) is the same as in 
equation (2.4). Hence the steady state is expounded as 
                           (𝑥, 𝑦, ?̅?) = (
1
𝑍∗+1
, 𝑍∗𝑍∗)                                                                     (2.8) 
 

















                                                    (2.9)  
 
Further we expound a point near to the constant steady state and let 𝑥 = 𝑥 + 𝑋,    
 𝑦 = 𝑦 + 𝑌        𝑎𝑛𝑑  𝑧 = ?̅? + 𝑍 
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We expand the functions in terms of f, g and h and applies the Taylor Series technique 
about the point (𝑥, 𝑦, 𝑧̅). We then adheres to the linear terms only and we obtain 
 




















]                                                                      (2.10) 
 
From equation 2.10, (A) represents the Jacobian matrix evaluated at (𝑥 , 𝑦, ?̅?). Hence 
matrix (A) is defined as 
  
𝐴 =  [
−𝑎1(?̅? + 1) −𝑎1?̅? 0
𝑎2𝑎3?̅? 𝑎2(𝑎3?̅? − 1) −
0 𝑎5 −𝑎5
𝑎4?̅?]                                                         (2.11) 
 
The stability of the developed model is further studied using eigenvalues from matrix (A) 
in equation (2.10). It was noted that the constant state of equation 2.10 is stationary, 
when no eigenvalue has positive real part. On the other hand if the entire eigenvalues 
have negative real part, then the determinant A≠ 0 
 
Proposition 2.2 
(I) Suppose  𝑎1, 𝑎2, 𝑎3  > 0, then the constant state of equation (2.10) and the 
linear system of equation (2.3) is asymptotically stable. On the other hand if 
𝑎3  < 1, then equation 2.3 is asymptotically unstable. 
(II) Further, if 𝑎1, 𝑎2, 𝑎4, 𝑎5 > 0  and   𝑎3  > 1, then the constant state of equation 
(2.10) and the linear system of equation (2.6) is asymptotically stable. 
 
 
Proof of Proposition 2.2 
We expound the characteristic equation of the Jacobian matrix (A) in equation (2.10) as:  
 
         𝑈𝑜(𝜆) =  𝜆
3 + (𝑏1 + 𝑑1)𝜆




𝑏1 = 𝑎1(1 + ?̅? ) + 𝑎2 + 𝑎5 + 𝑎4𝑧̅, 
                                           𝑏2 = 𝑎1(1 + ?̅? )(𝑎2 + 𝑎5 + 𝑎4𝑧̅) + 𝑎5(𝑎2 + 𝑎4(?̅? + 𝑧̅)), 
                                            𝑏3 = 𝑎1𝑎5(1 + ?̅?)(𝑎2 + 𝑎4(?̅? + 𝑧̅ )), 
𝑑1 = −𝑎2𝑎3?̅?, 
                                                         𝑑2 = −𝑎2𝑎3(𝑎1 + 𝑎5)?̅?, 
                                                         𝑑3 = −𝑎1𝑎2𝑎3𝑎5?̅?                                           (2.13) 
 
Next we substitute the steady state equation of equation (2.11) into equation (2.12), and 
obtain the criterion equation given by:  
 
                                                   (𝜆 + 𝑎1) (𝜆 + 𝑎1(1 − 𝑎3))(𝜆 + 𝑎5) = 0                   (2.14) 
 
Hence the eigenvalues of the Jacobian Matrix A, can now be written as 𝜆1 = −𝑎1 < 0, 
 𝜆2 = −𝑎5 < 0.  and 𝜆3 = − 𝑎2(1 − 𝑎3). Again if  𝑎3 < 1 and  𝜆3 < 0,  then the constant 
state of equation (2.5) is asymptotically stable. Conversely, if 𝑎3 > 1 and 𝜆3 > 0, then 
equation 2.8 is unstable. 
Further, if from proposition 2.2, 𝑎3 > 1, then the constant state of equation (2.6) exist at 
𝑧∗ > 0. It follows that by the Routh – Hurwitz criterion, all the roots of the characteristics 
equation in (2.12) have negative real part if and only if 
𝑏1 + 𝑑1 > 0,    𝑏3 + 𝑑3 > 0,      (𝑏1 + 𝑑1)(𝑏2 + 𝑑2) − (𝑏3 + 𝑑3) > 0                               (2.15) 
 
Hence, we verify equation (2.1), by substituting equation (2.8) into equation (2.12) and 
obtain the equations below: 
 






𝑏3 + 𝑑3 = 𝑎1𝑎5(1 + 𝑧
∗)(𝑎2 + 2𝑎4𝑧
∗) −






𝛽 = −𝑎1𝑎5(1 + 𝑧
∗ )(𝑎2 + 2𝑎4𝑧
∗) +
𝑎1𝑎2 𝑎3𝑎5  
1+𝑧∗










+ 𝑎1(𝑎2 + 𝑎5 + 𝑎4𝑧
∗ )(1 + 𝑧∗]                                      (2.16) 
 
 
Further, from equation (2.5) we write 𝑎2 and 𝑎3 as: 
                               𝑎2𝑎3 = 𝑎4(𝑧
∗)2 + 𝑎4𝑧
∗ + 𝑎2𝑧
∗ + 𝑎2                                              (2.17) 
 
Substituting equation (2.13) into equation (2.12) and simplifying all the parameters, we 
obtain 
 
𝑏1 + 𝑑1 = 𝑎1(1 + 𝑧
∗) + 𝑎5,           𝑏3 + 𝑑3 + 𝑧








∗)2 + 𝑎5(1 + 𝑧
∗))                 (2.18) 
 
Hence, in accordance with proposition 2.2, we conclude that equation (2.12) satisfies 
the conditions of proposition 2.2 and therefore asymptotically stable. 
 
Further, from the above deductions, patients with strong CTL will have a higher stable 
state and low viral haul. This indicates that patients with low CTL will demonstrate a 
higher rate of viral infection. Conditions in proposition 2.1 are satisfied by maintaining 
the physical parameters such as  𝛿1, 𝛿3, 𝛿4, 𝛿5, 𝑎3 > 1  𝑎𝑛𝑑 𝑎3 < 1. Hence, when  𝑎3 > 1, 
intimates a successful infection by the virus. Therefore the uninfected steady state in 
equation (2.5) relinquishes its stability, whilst the tainted steady state in equation (2.7) 
becomes stable.  
 
2.4     SUMMARY 
The focus of the chapter has been on three main basic sections, such as the 
background pertaining to HIV/ AIDS, biological background of the deadly disease and 
how to develop deterministic ODE models for further transformation to intracellular 
delay differential equation. The history of HIV has been referenced as early as 1920, 
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when HIV-1 in humans, was discovered through the blood samples of a man from 
Kinshasa, in the democratic republic of Congo. Genetic analysis further revealed the 
existence of HIV-2 in humans, which is less infectious than HIV-1 
The biological background has provided an insight on how the virus evades the human 
resistive system reliably. The query still remains on how, a particular virus is able to 
produce so many strains in a tainted individual.  
 
Currently chapter three, been the next chapter is aligned with the modelling of in vivo, in 
vitro and in silico analysis. Further, the chapter is incorporated with, within host 



















SCIENTIFIC MODELLING OF HIV  
3.0    INTRODUCTION 
Refreshingly chapter two has been a pointer to the background pertaining to HIV/ AIDS, 
biological background of the deadly disease and how to develop deterministic ODE 
models for further transformation to delay differential equation. Currently chapter three 
is aligned with the modelling of in vivo, in vitro and in silico analysis. The chapter further 




3.1.1    MODELLING IN TERMS OF IN VIVO ANALYSIS 
 
This type of analysis involves a careful study of an organism in its natural environment, 
hence application of in-vivo analysis to HIV/AIDS in the case of human, requires clinical 
trials [43, 48, 101]. A controlled group is carefully pursued and monitored and may 
sometimes be fruitful or unfruitful due to treatment interruption. This is because, a 
particular STI regime could be stopped earlier, when the trials are unsuccessful [18, 19]. 
Several approaches have been devised in monitoring or studying this menace and male 
circumcision [26, 27, 28], has been momentous in minimizing the spread of HIV. The 
use of animals such as infected SIV macaque monkey as proxy, instead of humans has 
been insightful in providing useful information to scientist about HIV advancement. This 
is because HIV belongs to a family of virus which cannot propagate on their own [14, 
48, 63], yet remains very virulent inside a host cell. A lot of viruses belong to the family 
of HIV and possess similar species characteristics. Scientists are therefore able to track 
a number of hosts in discovering HIV vaccine [29, 30]. Notwithstanding, clinical trials 
with humans are still considered as authentic, due to the slight difference between HIV 
and SIV. However, the chimeric mice have proven to be a good proxy for human, since 
it demonstrates similar cell characteristics and can be infected with HIV as well. Further, 
they are easy to produce in large quantities and have cells which resemble the complex 
human immune system, compared to using a costly infected chimpanzee as proxy [25]. 
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It is however noted that the slow infection rate of HIV requires a longer amount of time 
in obtaining results. The earliest rate of obtaining HIV results is associated with feline 
immunodeficiency virus (FIV), an ‘HIV-like sickness’ which takes 6 to 8 years before the 
tainted individual dies. This contagion is similar to HIV progression, especially when the 
progression occurs in the soonest of time [26,154,155, 156, 157]. The in-vivo approach 
of modelling HIV is credited for the development and testing of new drugs. 
 
 
3.1.2    MODELLING IN TERMS OF IN VITRO ANALYSIS 
This method of modelling, in terms of in vitro analysis has been the pointer and success 
to the recognition of HIV. It requires scientist to obtain information, or data outside the 
defined environment of the organism under consideration. This modelling revolves 
around molecular biology but unfortunately, results obtained by this type of analysis are 




3.1.3    MODELLING IN TERMS OF IN SILICO 
In the quest of discovering a vaccine for HIV by scientist [29, 30, 72], scientist have 
applied several approaches and modelling techniques, and the chief among such, is the 
in vivo and in vitro analysis. However, in-vivo and in-vitro analysis require mathematical 
simulations to integrate the pieces of information procured from such analysis or 
modelling. The use of computer simulations in such biological experiments is called in 
silico analysis. This scientific approach [39] intimates that mathematical models are 




3.2.   REVIEW OF PRE- DETERMINISTIC MODELLING  
 Modelling epidemic diseases using mathematical concepts has not only broadened our 
knowledge on HIV over the last decade [1, 2, 3, 4, 5, 6], but has also provided answers 
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and clues to areas of the pandemic that has not been explored. Several researchers 
have invented stochastic and deterministic models, which have imparted positively to 
the control of the virus and also tremendously on drug therapy [24, 25]. Over the years 
most scientist have resulted to the top down deterministic approach [42, 137], which has 
yielded successful results. Therefore application of mathematical concepts to epidemic 
disease has been progressive, from single-target-cell models to multi-target-cell models 
[40, 53, 54, 64, 65, 66]. 
 
Reibnegger et al. were among the early scientist who focused their discoveries on the 
immune system. According to Reibnegger et al. infected cells are progressively 
depleted in the passage of time leading to AIDS eventually. This is supported by 
Perelson et al. who initiated a categorized DDE model with various CD4+T cells. His 
compartment or population was embodied with Virgin cells, active cells and memory 
cells, which interacts with the HIV virus; hence the virus was produced by the active 
cells. Memory cells were only involved when they were triggered to beget a virus, a 
case similar to latent cells which are only activated when therapy is stopped [34, 116]. 
In congruence to the early discoveries made on the progression of HIV, Nowak et al, 
contributed to the discoveries by focusing on the dominant duplicative rate of the virus, 
as a platform for antigenic diversity and a minimum margin for the immune system to 
operate. He intimated that HIV invasion beyond the minimum margin, leads to the 
production of more viral strains. The production of viral strains is inhibited by the human 
resistive system and hence AIDS intercept [38, 39, 75, 76, 77, 78].  Therefore, Nowak’s 
model is aligned with the high replication rate of the virus and the regulation of DRM 
associated with therapy regime.  
 
Nevertheless precise computation of viral haul has changed the focus on high viral 
replication drastically and making it possible to access a person’s viral haul in the 






3.3.1    THE SINGLE-TARGET-CELL MODEL (STC) 
Refreshingly, the decay rate of a virus was precisely computed for the first time in the 
mid-1990, based on the progress made on current protease inhibitor (PI) drugs. The 
computation was made possible by administering (PI) drugs in relation to other drugs, 
which inhibited viral replication. However viral suppression by drugs could not provide a 
continual sustenance, hence Wei et al, in 1995 explained the consistent replication of 
the virus. He indicated that the replication of the virus was at maximum compared with 
previous information [50, 32]. Per Wei et al. the least computation estimate of viral 
production was 108 virions per day, based on 100% efficient drug usage [29, 100].The 
high production rate was attributed to imminent resistance to mono-therapy. However, 
after few weeks of administering the drugs [24, 25], some of the virus became mutants 
to the drugs and reduced its efficacy.  
 
Hence, Perelson et al. contributed to the viral production rate by expounding equation 
3.1 and hence developed a short term model. The model explains the rapid 
multiplication of the virus on short term basis [149, 162]. Hence the model operates on 
the assumption that pre-treatment viral levels are constant, when therapy is aligned to a 
stable system. Clinical latency was also acknowledged, whilst viral load disintegrates 
[34, 116,]. The developed STC model is composed of four key cells, aimed at describing 












= (1 − 𝜖𝑝)𝑁𝑇𝛿𝑇𝑃




∗(𝑡) − 𝑐𝑉𝑛𝑖(𝑡)                                                                                               (3.1) 
 
The above equation is called the top-down deterministic model, with the following 
parameters: 𝑇𝑝  = infected virus,  𝜆𝑝 = rate of production of uninfected virus. 𝛿𝑝=rate at 
which the cells die, 𝑉𝑖= rate of change of infectious virus, 𝛿= death rate of infectious 
virus, 𝜖𝑟𝑡 = reverse transcription inhibitor, 𝑁𝑇 = virus production rate, C = rate at which 
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virus die, 𝑉𝑛𝑖 = non-infectious virus. Table 3.1 depicts some of the parameters and their 
definitions for the single target cell model. 
 
 




key target cells         














Amount of Non-tainted virus 
 




3.3.2   THE MULTIPLE-TARGET-CELL MODEL (MTC) 
The foundation for a more complex model has been echoed by the above STC model in 
section 3.3.1. However, the introduction of complex parameters have influenced the 
precision of the STC model and hence switching to models which incorporates key 
parameters relevant in dealing with treatment options [78, 79]. It is noted that such 
complexity could not be dealt with by the short-term ODE models, but the multiple target 
cell model. Multiple target-cell-models are oriented from increased number of target 
cells, such as primary and secondary target cells. It further permits several viral 
production rates by acknowledging chronic infection and increased details on the 
immune system. Multiple target cell models are further aligned with modelling of non-
zero viral haul which is vital for long duration dynamics of treatment options [62, 165]. 
Two types of multiple target cell models are considered for discussion below; the 
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multiple target cell model for chronic infection (MTC-CI) and multiple-target-cell model 
for immune response (MTC-IR)  
 
 
3.3.3     MULTIPLE-TARGET-CELL MODEL FOR CHRONIC INFECTION (MTC-CI) 
It is worth to note that small residual of infected cells, ignites a re-stimulation of high 
viral replication. This is attributed to the particle nature of viruses outside a host cell and 
the tenacity to ignite an infection within a living cell [82, 165]. Hence the evolution of 
models with longer dynamics and capacity, such as the multiple targets cell model for 
chronic infection (MTC-CI). The MTC-CI model is appropriate to facilitate such complex 




= 𝜆𝑝 − 𝛿𝑝𝑇𝑃 − (1 − 𝜖)𝑘𝑝𝑉𝑇𝑃  
𝑑𝑇𝑠
𝑑𝑡














= 𝛼(1 − 𝜖)𝑘𝑝𝑉𝑇𝑃 − 𝜇𝐶𝑇𝑝












∗) − 𝑐𝑉  
Comparatively, equation (3.2) is heterogeneous to equation (3.1) and therefore 
acknowledges the incorporation of secondary target cells, (𝑇𝑝 and 𝑇𝑠) as parameters. 
Other parameters include the amount of virions produced over a period of time 
represented by (𝐶𝑝 and 𝐶𝑠). Additional variables and definitions for equation 3.2 are 














































TABLE 3.2: MTC-CI MODEL (Variables for the model and their definitions) 
 
 
3.3.4    THE MULTIPLE-TARGET-CELL MODEL FOR IMMUNE RESPONSE (MTC-IR) 
The (MTC-IR) model deals with prolonged HIV advancement and the embodiment of a 
more precise feature of the human resistive system, which supports further evaluation 
of viral reflex. MTC-IR models as described above are more detailed when embodied 





= 𝜆𝑝 − 𝛿𝑝𝑇𝑝 − (1 − 𝜖)𝑘𝑝𝑉𝑇𝑃 
𝑑𝑇𝑠
𝑑𝑡




































𝐸 − 𝛿𝐸𝐸                                                                (3.3) 
  
The equation above is a multifold model similar to the MTC-CI model discussed above. 
It is concentrated on two types of cells, namely CD4+T cells and macrophages cells 
which are fragile to HIV infection.  However additional cells have been added to the 
model due to increase in the number of compartments involved. The operations of 
equation 3.3 are peculiar to the MTC-CI model but short of the chronic infection 
component represented by (𝐶𝑝 and 𝐶𝑠).  
 
Notwithstanding, the above model compared to the MTC-CI model is further activated 
by the removal of the following parameters: tainted cells represented by 
(𝑚𝑝𝐸𝑇𝑝
∗ 𝑎𝑛𝑑 𝑚𝑠) and effector cells (E), Additional variables for the model are defined in 


















































3.3.5     DOUBLING-TIME AND HALF-LIFE 
The duration relevant for a specified group of virus to increase in size when treatment 
options have been discontinued is called viral doubling-time. Find below the formula 
used for calculating the viral doubling-time 
 






                                                                                                   (3.4) 
Where 𝑇𝑑 represents the viral doubling-time, 𝑡 1 and 𝑡2 represents the growth duration, 
stipulated by (𝑞1,𝑞2). The growth rate is exponential and is not applicable to the whole 
model for a given infection. It is however significant in the maiden stages of the 
infection, where there is limited amount of infection.  The parameter  ln(2) is the 
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duration required for the system to double in size. Hence when a cell fails to double in 
size but rather reduce in size, the process is called half-life. Half-life occurs when a 
system dissociates with respect to time as a result of therapy removal. Find below the 










                                                                                                    (3.5) 
 
Equation (3.4) is similar to equation (3.5), the difference lays with the ratio  
𝑞2
𝑞1⁄ . The 
presence of 
𝑞2
𝑞1⁄  accounts for the duration needed for a system to decrease in size. 
Doubling-time and half-life can be calculated easily by using clinical viral load data. 
Calculations made on viral doubling time and half-life is used in determining the 
effectiveness of intracellular delay in the model. 
 
 
3.4     MODELLING MTC-CI WITH INTRACELLULAR DELAY (MTC-CI-ID) 
In an attempt to model an MTC-CI, we initiate a classical model defined as follows: 
?̇? = Λ − (𝛼(𝑥) + 𝛾1 + 𝜇1)𝑆  
𝐼 = 𝛼(𝑥)𝑆 − ( +̇ 𝜉 + 𝜆 + 𝜇1)𝐼  
𝐼?̇? = 𝜉𝐼 − (𝜃 + 𝜇 + 𝑋 + 𝜇1)𝐼𝐴  
𝐼?̇? = 𝜖𝐼 − (𝜂 + 𝜑 + 𝜇1)𝐼𝐷  
𝐼?̇? = 𝜂𝐼𝐷 + 𝜃𝐼𝐴 − (𝜐 + 𝜉 + 𝜇1)𝐼𝑅                                                                         (3.6) 
𝐼?̇? = 𝜇𝐼𝐴 + 𝜐𝐼𝑅 − (𝜎 + 𝜏 + 𝜇1)𝐼𝑇  
?̇? = 𝜆𝐼 + 𝜑𝐼𝐷 + 𝑋𝐼𝐴 + 𝜉𝐼𝑅 + 𝜎𝐼𝑇 − (𝜙 + 𝜇1)𝑅  
?̇? = 𝜏𝐼𝑇 − 𝜇1𝐷  
?̇? = 𝛾1𝑆 + 𝜙𝑅 − 𝜇1𝑉 − 𝜏𝐼𝑇  
 





?̇? = ?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅,𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
𝐼̇ = 𝐼(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
𝐼?̇? = 𝐼𝐴(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
𝐼?̇? = 𝐼𝐷(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
𝐼?̇? = 𝐼𝑅(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)                                                                         (3.7) 
𝐼?̇? = 𝐼𝑇(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
?̇? = ?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
𝐷 = ?̃?̇ (𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
?̇? = ?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)  
 
Equating 3.6 and 3.7, we obtain the following: 
 
?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅,𝐼𝑇 , 𝑅, 𝐷, 𝑉) =  Λ − (𝛼(𝑥) + 𝛾1 + 𝜇1)𝑆  
 𝐼(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝛼(𝑥)𝑆 − ( +̇ 𝜉 + 𝜆 + 𝜇1)𝐼  
𝐼𝐴(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜉𝐼 − (𝜃 + 𝜇 + 𝑋 + 𝜇1)𝐼𝐴  
𝐼𝐷(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜖𝐼 − (𝜂 + 𝜑 + 𝜇1)𝐼𝐷  
𝐼𝑅(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜂𝐼𝐷 + 𝜃𝐼𝐴 − (𝜐 + 𝜉 + 𝜇1)𝐼𝑅                                    (3.8) 
𝐼𝑇(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜇𝐼𝐴 + 𝜐𝐼𝑅 − (𝜎 + 𝜏 + 𝜇1)𝐼𝑇  
?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜆𝐼 + 𝜑𝐼𝐷 + 𝑋𝐼𝐴 + 𝜉𝐼𝑅 + 𝜎𝐼𝑇 − (𝜙 + 𝜇1)𝑅  
?̇̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝜏𝐼𝑇 − 𝜇1𝐷  
?̃?(𝑡, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉) = 𝛾1𝑆 + 𝜙𝑅 − 𝜇1𝑉 − 𝜏𝐼𝑇  
 
Next we apply the fractal- fractional integral with exponential kernel to equation 3.8 and 
obtain the following: 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)



























, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 
 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)





, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 
 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)





, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 


















, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)





, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)







, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 
 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)





, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 
 












𝑃−1, 𝑅𝑃−1, 𝐷𝑃−1, 𝑉𝑃−1)





, 𝑆, 𝐼, 𝐼𝐴, 𝐼𝐷 , 𝐼𝑅 , 𝐼𝑇 , 𝑅, 𝐷, 𝑉)𝑑𝜏 
 
 Now we introduce into equation 3.9 the following; primary target cell 𝑇𝑝, contagious 
virus V, Macrophage cells 𝑇𝑠 and effector cells ∈ and differentiate the system of 
equations with respect to time (t). When the parameters were simplified, the equations 




= 𝜆𝑝 − 𝛿𝑝𝑇𝑃 − (1 − 𝜖)𝑘𝑝𝑉𝑇𝑃  
𝑑𝑇𝑠
𝑑𝑡









= (1 − 𝛼)(1 − 𝑓𝜖)𝑘𝑠𝑉𝑇𝑠 − 𝛿𝑇𝑠




= 𝛼(1 − 𝜖)𝑘𝑝𝑉𝑇𝑃 − 𝜇𝐶𝑇𝑝














∗) − 𝑐𝑉  
Next we consolidate into equation 3.10 the delay component, which yields the MTC-CI-
ID model as shown below: 
𝑑𝑇𝑝(𝑡)
𝑑𝑡
= 𝜆𝑝 − 𝛿𝑝𝑇𝑃(𝑡) − (1 − 𝜖)𝑘𝑝𝑉(𝑡)𝑇𝑃(𝑡)  
𝑑𝑇𝑠(𝑡)
𝑑𝑡




= (1 − 𝛼)(1 − 𝜖)𝑘𝑝𝑉(𝑡 − 𝜏)𝑇𝑃(𝑡 − 𝜏)𝑒
−𝛿𝜏 − 𝛿𝑇𝑝










= 𝛼(1 − 𝜖)𝑘𝑝𝑉(𝑡 − 𝜏)𝑇𝑃(𝑡 − 𝜏)𝑒
𝜇𝜏 − 𝜇𝐶𝑇𝑝












∗(𝑡)) − 𝑐𝑉(𝑡)  
 
From the above model, 𝑇𝑝 represents the untainted CD4+ T cells, 𝑇𝑠 the untainted 
secondary cell (macrophage), 𝑇𝑝
∗ and  𝑇𝑠
∗ respectively represents tainted CD4+T cells 
and macrophage, V denotes viral delay component, 𝑒−𝛿𝜏 represents the rate at which 











MODELLING OF INTRACELLUAR DELAY AND THERAPY INTERRUPTIONS 
4.0   INTRODUCTION 
Chapter three was engaging with the modelling of in vivo, in vitro and in silico analysis. 
It further dealt with within host deterministic modelling of HIV/AIDS continual and 
modelling of intracellular delay. Chapter four is interlocked with modelling of intracellular 
delay, well posedness and existence of equilibrium points. A further consideration is 
given to the global stability of equilibrium and the endemic equilibrium. Existence and 
proof for the existence of Hopf Bifurcation are simulated by this chapter and a 
confirmation of the results by numerical simulation. The chapter finally concludes on the 
analysis of structured treatment interruptions. 
 
 
4.1      MODELLING INTRACELLULAR DELAY  
Delay differential equations (DDEs) have been valuable for innumerable years in control 
theory and recently interrelated to biological and mathematical models. Most biological 
frames [36] have time delay embedded in them, yet few scientist collaborate them due 
to the intricacies they stimulate. The principal intricacies in studying DDEs lie in their 
solitary transcendental character. 
Delay challenges invariably ushers to an immeasurable measure of prevalence. Hence, 
they are constantly unraveled using numerical methods, asymptotic solutions, 
approximations and graphical accessions. In this paper, we first formulate a system of 
DDE’S expounded as follows 
 
 








= 𝑎1(1 − 𝑥𝑦 − 𝑥)
  𝑑𝑦
𝑑𝑡
= 𝑎2(𝑎3𝑥1𝑦1 − 𝑦) − 𝑎4𝑦𝑧
𝑑𝑧
𝑑𝑡
= 𝑎3(𝑦 − 𝑧)




The term 𝑎2𝑎3𝑥1𝑦1, represents the rate equation and reflects a boundless time lag 
between the infection of CD4+T-cell and the staging of new virions. Next we consider 
the well posedness and existence of equilibrium points. 
 
 
4.2   WELL POSEDNESS AND EXISTENCE OF EQUILIBRIUM POINTS 




= 𝐹(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1)   
𝑑𝑦
𝑑𝑡
= 𝐺(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1)                                                                                   (4.2) 
𝑑𝑧
𝑑𝑡
= 𝐻(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1)  
 
Equating 4.1 and 4.2, yields 
𝐹(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1) ≔ 𝑎1(1 − 𝑥𝑦 − 𝑥)  
𝐺(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1) ≔ 𝑎2( 𝑎3, 𝑥1, 𝑦1 − 𝑦) − 𝑎4𝑦𝑧                                               (4.3) 
𝐻(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1) ≔ 𝑎5(𝑦 − 𝑧)   
Further, we define a steady state for equation (4.2) in terms of  (?̅?, ?̅? , 𝑧̅) and procure the 
equations below: 
F(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0 
G(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0                                                                                   (4.4) 
H(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0  
 
PROPOSITION 4.1 
If 𝑎2𝑎3 and 𝑧1: = 𝑇𝜏𝑧, then the steady state solution of equation (4.2) is in unison with the 




Consider an immutable function S(t) and its derivative  
𝑑𝑠
𝑑𝑡
 , assuming that the derivative 






  , then :  
F(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0,    G(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0   and    H(?̅?, ?̅?, 𝑧̅ , ?̅?1, ?̅?1, 𝑧1̅) = 0 , hence 
equations (4.2) and (4.4) have the same unvarying states.  
Further, by codifying a neighborhood close to the unvarying state solution, we let 
𝑥 = ?̅? + 𝑋 ,      𝑦 = ?̅? + 𝑌  ,   𝑧 = 𝑧̅ + 𝑍,   𝑥1 = ?̅? + 𝑋1,    𝑦1 = ?̅? + 𝑌1   𝑎𝑛𝑑  𝑧1 = 𝑧̅ + 𝑍1  
 
Next, we exploit the Taylor series about the point (?̅?, 𝑦 ̅, 𝑧̅) and withholding only the 




= −𝑎1(?̅? + 1)𝑋 − 𝑎1?̅?𝑌, 
𝑑𝑌
𝑑𝑡
= 𝑎2𝑎3?̅?𝑋1 + [𝑎2(𝑎3?̅?𝑌1 − 𝑌) − 𝑎4𝑧̅𝑌] − 𝑎4?̅?𝑍       𝑎𝑛𝑑                               (4.5) 
𝑑𝑍
𝑑𝑡
= 𝑎5𝑌 − 𝑎5𝑍  
 

















−𝑎1(?̅? + 1) −𝑎1?̅? 0
𝑎2𝑎3?̅?𝑒
−𝜆𝑡 𝑎2(𝑎3?̅?𝑒






⌋                            (4.6) 
 
Next we let  𝐵 = ⌊
−𝑎1(?̅? + 1) −𝑎1?̅? 0
𝑎2𝑎3?̅?𝑒
−𝜆𝑡 𝑎2(𝑎3?̅?𝑒
−𝜆𝑡 − 1) − 𝑎4𝑧̅ −𝑎4?̅?
0 𝑎5 −𝑎5
⌋   
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Where B is the coefficient matrix of the linearized system and  𝜆 is the eigenvalue of 
matrix B. Hence the unvarying state of the delay system can be explored in terms of the 
eigenvalues of matrix B.  
 
4.3     GLOBAL STABILITY OF EQUILIBRIUM  𝐸𝑂 
In this section, we proceed by analyzing the universal stability of the disease-free 






= 𝐹(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1),   
𝑑𝑦
𝑑𝑡
= 𝐺(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1)  and   
𝑑𝑧
𝑑𝑡
= 𝐻(𝑥, 𝑦, 𝑧, 𝑥1, 𝑦1, 𝑧1), then  
 
(𝑥𝑜 , 𝑦𝑜, 𝑧𝑜) is stable if  𝜖 > 0  and 𝛿 > 0 for  (𝑥, 𝑦, 𝑧) when 
 
[𝑥(𝑡𝑜) − 𝑥𝑜]
2 + [𝑦(𝑡𝑜) − 𝑦𝑜]
2 + [𝑧(𝑡𝑜) − 𝑧𝑜]
2  < 𝛿2                                               (4.7) 
 
Given that  𝑡𝑜  ∈ [𝑡1 − 𝜏, 𝑡1], 𝑡ℎ𝑒𝑛  [𝑥(𝑡) − 𝑥𝑜 ]
2 + [𝑦(𝑡) − 𝑦𝑜]
2 +  [𝑧(𝑡) − 𝑧𝑜 ]
2  <∈2  for all 
𝑡 > 𝑡1. 
On the other hand if (𝑥𝑜 , 𝑦𝑜 , 𝑧𝑜) is stable and 𝛿 is chosen so that equation (4.7) is 
elucidated as [𝑥(𝑡), 𝑦(𝑡), 𝑧(𝑡)   → (𝑥𝑜 , 𝑦𝑜 , 𝑧𝑜)]. Then as 𝑡 →  ∞, (𝑥𝑜 , 𝑦𝑜 , 𝑧𝑜) is globally 
asymptotically stable.  
 
PROPOSITION 4.2 
Suppose  𝑎1, 𝑎2, 𝑎3, 𝑎5 > 0 ∶ 
(i). then if 𝑎3 < 1, then the unvarying state of equation (4.1) of the system (4.2) is 
universally asymptotically stable for 𝜏 ≥ 0. Hence  𝐸𝑂 is stable 
(ii). If 𝑎3 > 1, then the unvarying state of equation (4.1) of the system (4.2) is globally 






Suppose the characteristic equation of matrix B is written as  
𝑈(𝜆) = 𝜆3 +  𝑏1𝜆
2 +  𝑏2𝜆 +  𝑏3 + (𝑑1𝜆
2 + 𝑑2𝜆 + 𝑑3)𝑒
−𝜏𝜆 = 0                                    (4.8) 
Now if 𝜏 = 0 , then there is no delay in equation 4.8, hence proposition 4.2 reduces to 
proposition 4.1  
 
Conversely, when 𝜏 > 0, and we surrogate the unvarying state of equations  (4.1) and 
(4.3) and solve, we generate the characteristic equation  
(𝜆 + 𝑎1 )(𝜆 + 𝑎2 − 𝑎2𝑎3𝑒
−𝜆𝜏)(𝜆 + 𝑎5) = 0  
 
Next, by considering the unvarying state of equation 4.1, we ascertain that matrix B has 
three eigenvalues: 𝜆1 = −𝑎1 < 0, 𝜆2 = −𝑎5  < 0     and 𝜆3 in the form 
𝜆3 + 𝑎2(𝑎3𝑒
−𝜏𝜆3 − 1) = 0    
 
Therefore, to find the location of   𝜆3, we propose a function of the form 
 𝑢(𝑡) ≔ 𝑡 + 𝑎2 − 𝑎2𝑎3𝑒
−𝜆𝜏, where 𝑡 ∈ 𝑅 
By differentiating, we obtain 𝑢′(𝑡) = 1 + 𝑎2𝑎3𝜏𝑒
−𝜆𝜏, which is always positive, hence the 
limit of the original equation is written as  lim𝑡→∞ 𝑢(𝑡) = −∞ and  
lim𝑡→∞ 𝑢(𝑡) = ∞ . Therefore u(t)  has a distinctive zero revealed as 𝑢(0) = 𝑎2(1 − 𝑎3) .  
 
Hence we conclude that if 𝑎3 < 1, 𝑢(0) > 0 and 𝜆3 < 0. Then the unvarying state of 
equation (4.6) is globally asymptotically stable for 𝜏 > 0.  
 
Conversely if 𝑎3 > 1, then we conclude that the unvarying state of equation (4.1) is 
globally asymptotically unstable for 𝑎3 < 0 ,  𝜆3 > 0 and 𝜏 > 0 
 
 
4.4    THE ENDEMIC EQUILIBRIUM  
The endemic equilibrium 𝐸∗ is obtained by filtering the real and imaginary parts from the 
equation below   
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[𝑏3 + 𝑏2𝛼 + 𝑏1𝛼
2 + 𝛼3 − 𝑏1𝜔
2 − 3𝛼𝜔2 + 𝑖(𝑏2𝜔 + 2𝑏1𝛼𝜔 + 3𝛼
2𝜔 − 𝜔3) + 𝑒−𝜏𝛼[(0𝑑2𝜔 +
2𝑑1𝛼𝜔)𝑠𝑖𝑛𝜔𝜏 + (𝑑3 + 𝑑2𝛼 + 𝑑1𝛼
2 − 𝑑1𝜔
2)𝑐𝑜𝑠𝜔𝜏 + 𝑖𝑒−𝜏𝛼  
[(𝑑1𝜔
2 − 𝑑3 − 𝑑2𝛼 − 𝑑1𝛼
2)𝑠𝑖𝑛𝜔𝜏 + (𝑑2𝜔 + 2𝑑1𝜔)𝑐𝑜𝑠𝜔𝜏] = 0                                   (4.9) 
 
which yields 
𝑑2𝜔𝑠𝑖𝑛𝜔𝜏 + (𝑑3 − 𝑑1𝜔
2)𝑐𝑜𝑠𝜔𝜏 = 𝑏1𝜔
2 − 𝑏3                                                              (4.10) 
𝑑2𝜔𝑐𝑜𝑠𝜔𝜏 − (𝑑3 − 𝑑1𝜔
2)𝑠𝑖𝑛𝜔𝜏 = 𝜔3 − 𝑏2𝜔                                                               (4.11) 
 
Summing the squares of equations (4.10) and (4.11)  
𝑢(𝜔) ≔ 𝜔6 + (𝑏1
2 − 2𝑏2 − 𝑑1
2) 𝜔4 + (𝑏2
2 − 2𝑏1𝑏3 + 2𝑑1𝑑3 − 𝑑2
2)𝜔2 + 𝑏3
2 − 𝑑3
2 = 0      (4.12) 
 
We further exploit equation (4.12) by surrogating the parameters below 
𝑚 ≔ 𝜔2,    𝑝 ≔ 𝑏1
2 − 2𝑏2 − 𝑑1
2,   𝑞 ≔ 𝑏2
2 − 2𝑏1𝑏3 + 2𝑑1𝑑3 − 𝑑2
2, 𝑎𝑛𝑑  𝑟 ≔ 𝑏3
2 − 𝑑3
2   
 
Hence, the new equation reads           
𝑘(𝑚) =  𝑚3 + 𝑝𝑚2 + 𝑞𝑚 + 𝑟 = 0                                                                               (4.13) 
 
LEMMA 4.1 
Suppose 𝜏 > 0 then equation (4.13) has no positive real root, hence all the roots have 
negative real parts. 
 
PROOF  
Since equation (4.13) has no positive root, then 𝜔 is not the root of equation (4.12). 
Therefore for any real number 𝜔, the value of 𝑖𝜔 is also not the root of equation (4.12), 
hence 𝜆(𝜏𝑐 = 𝑖𝜔(𝜏𝑐) is not the root of equation (4.12). This implies that only one positive 
real root exist for equation (4.13). Hence differentiating equation 4.13 yields 
 
𝑘′(𝑚) = 3𝑚2 + 2𝑝𝑚 + 𝑞                                                                                            (4.14) 
 




−𝑝 + √𝑝2 − 3𝑞
3
    𝑎𝑛𝑑  





(i). if  𝑟 < 0    then it follows that 𝑝2 − 3𝑞 > 0  has a positive root, provided 𝑝 < 0  
(ii) On the other hand if 𝑟 > 0  then 𝑝2 − 3𝑞 < 0, has no positive real roots. 
 
PROOF  
(i). Suppose condition (i) holds and 𝑟 < 0, then k(0) = 𝑟 < 0, hence lim𝑚→∞  𝑘(𝑚) = ∞. 
Exploiting the intermediate value theorem, equation (4.14) yields 𝑡𝑜 as a positive root 
and therefore 𝑘(𝑡𝑜) = 0.  
 
Conversely, if condition (ii) holds for which 𝑟 > 0  and 𝑝2 − 3𝑞 < 0, then 𝑚𝑜 is real, for 
which  𝑚𝑜  > 0. Since  𝑘(0) = 𝑟 > 0 𝑎𝑛𝑑 𝑘(𝑚𝑜) < 0, then by the intermediate value 
theorem, k has zero between the origin and 𝑚𝑜  
 
(ii). conversely, if 𝑞 >
1
3
𝑝2 then the zeros of 𝑚𝑜 𝑎𝑛𝑑 𝑚1 𝑜𝑓 𝐾
′(𝑚) are not real. 





𝑝2 ≥ 0, has no real roots, given that 𝐾 is an increasing function 
where 𝐾(0) = 𝑟 ≥ 0. We conclude that the model has a unique endemic equilibrium 
which is asymptotically stable if and only if 𝑅𝑜 > 1, otherwise unstable. This unique 
endemic equilibrium occurs at  𝜏 ≥ 0 
 
  
4.5.    EXISTENCE OF HOPF BIFURCATION 
We introduce the Hopf bifurcation and therefore appraise the 3- dimensional system of 





= 𝐹(𝑥, 𝑦, 𝑧, 𝜏)  
𝑑𝑦
𝑑𝑡




= 𝐻(𝑥, 𝑦, 𝑧, 𝜏)           
The following conditions holds if : 
(i). 𝐹(?̅?, ?̅?, 𝑧̅, 𝜏) = 𝐺(?̅?, ?̅?, 𝑧̅, 𝜏) = 𝐻(?̅?, ?̅?, 𝑧̅, 𝜏) = 0 , then  𝜏𝑐 𝑎𝑛𝑑 (?̅?, ?̅?, 𝑧̅, )   remains as a 
steady state solution for equation (4.13) 
(ii). F, G and H are analytic in terms of (𝑥, 𝑡, 𝑧), then they are within the neighborhood of  
(?̅?, ?̅?, 𝑧̅, 𝜏𝑐) 
(iii). the Jacobian matrix of equation (4.6) at (?̅?, ?̅?, 𝑧̅, 𝜏) has a pair of complex conjugate 
eigenvalues, 𝜆 𝑎𝑛𝑑 ?̅?, then   
𝜆(𝑡) = 𝛼(𝜏) + 𝑖𝜔(𝜏) ,    𝜔(𝜏𝑐) = 𝜔𝑐 > 0, 𝛼(𝜏𝑐) = 0    𝑎𝑛𝑑 
𝑑𝛼(𝜏)
𝑑𝑟
𝐼𝜏 = 𝜏𝐶 ≠ 0               (4.16)                                           
 (iv). the remaining eigenvalues of the Jacobian matrix at (?̅?, ?̅?, 𝑧̅, 𝜏𝑐) have strictly 
negative real part. Then the system (4.9) has a family of periodic solution: ∈𝐻> 0 and 
analytic function 𝜏𝐻(𝜖) = ∑ ∞𝑇𝑖
𝐻 ∈𝑖 ,2  𝑤ℎ𝑒𝑟𝑒 0 <∈<∈𝐻. Hence, 𝑇
𝐻(∈)𝑜𝑓 𝑝∈(𝑡) is analytic 




(1 + ∑  2
∞
𝑇𝑖
𝐻 ∈𝑖)(0 <∈<∈𝐻)                                                                  (4.17) 
 
Next, we exploit the parameters of the analytic function to ensure the occurrence of 
Hopf bifurcation. Hence we denote the positive roots of equation (4.1) by 
𝑚𝑗 , 𝑗, 𝑤ℎ𝑒𝑟𝑒  𝑗 ∈ [0,1,2], depending on the number of positive roots in the equation. 
Therefore equation (4.9) has six positive roots such as 𝜔𝑗, 𝜆 = 𝑖𝜔 and ±√𝑚𝑗  𝑤ℎ𝑒𝑟𝑒  𝑗 =




















                                 (4.18) 
Where 𝑗 = 0, 1,2 𝑎𝑛𝑑 𝑛 = 1,2, …. 




(𝜏) > 0, 0 ≤ 𝑗 ≤ 2, 𝑛 ≥ 1}                                                                 (4.19) 
Where 𝜔𝑐 = 𝜔𝑗𝑐  
 
THEOREM 4.1 
Consider the time lag 𝜏 and the critical time lag 𝜏𝑐 𝑎𝑛𝑑 𝜔𝑐 as defined in equation (4.13) 
and suppose  3𝜔𝑐
6 + 2𝑝𝜔𝑐
4 + 𝑞𝜔𝑐
2 ≠ 0 then the system of delay differential equation in 




We show that   
𝑑𝛼(𝜏 )
𝑑𝜏
𝐼𝜏 = 𝜏𝐶 ≠ 0                                                                                (4.20) 
The existence of Equation (4.14) personifies the occurrence of Hopf bifurcation. Hence 
equating the real and imaginary parts of equations (4.10) and (4.11) to zero, we obtain 
the following 
𝑒−𝜏𝛼[(𝑑2 + 2𝑑1𝛼)𝜔𝑠𝑖𝑛𝜔𝜏 + [(𝑑3 + 𝑑2𝛼 + 𝑑1(𝛼
2 − 𝜔2)] cos𝜔𝜏] =  
(𝑏1 + 3𝛼)𝜔
2 − 𝑏3 − 𝑏2𝛼 − 𝑏1𝛼
2 − 𝛼3]                                                                       (4.21) 
and 
 (𝑒−𝜏𝛼[(𝑑1𝜔
2 + 𝑑3 − 𝑑2𝛼 − 𝑑1𝛼
2)𝑠𝑖𝑛𝜔𝜏 + (𝑑2𝜔 + 2𝑑1𝛼𝜔)𝑐𝑜𝑠𝜔] = 𝜔
3 − 𝑏2𝜔 − 2𝑏1𝛼𝜔 −
3𝛼2𝜔                                                                                                                         (4.22)   
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Further, we differentiate equations (4.21) and (4.22) with respect to 𝜏 and evaluate at 





| 𝜏 = 𝜏𝑐 − 𝐸2
𝑑𝛼
𝑑𝜏




| 𝜏 = 𝜏𝑐 − 𝐸1
𝑑𝛼
𝑑𝜏
| 𝜏 = 𝜏𝑐 = 𝐸3𝑠𝑖𝑛𝜔𝑐𝜏𝑐 + 𝐸4𝑐𝑜𝑠𝜔𝑐𝜏𝑐                                               (4.24) 
 
Where 𝐸1 ≔ 2𝑏1𝜔𝑐 + (2𝑑1𝜔𝑐 − 𝜏𝑐𝑑2𝜔𝑐)𝑐𝑜𝑠𝜔𝑐𝜏𝑐 + (𝜏𝑐𝑑3 − 𝑑2 − 𝜏𝑐𝑑1𝜔𝑐
2)𝑠𝑖𝑛𝜔𝑐𝜏𝑐 
𝐸2 ≔ 𝑏2 − 3𝜔𝑐
2 + (𝑑2 + 𝜏𝑐𝑑1𝜔𝑐
2 − 𝜏𝑐𝑑3)𝑐𝑜𝑠𝜔𝑐𝜏𝑐 +(2𝑑1𝜔𝑐 − 𝜏𝑐𝑑2𝜔𝑐)𝑠𝑖𝑛𝜔𝑐𝜔𝑐 
 𝐸3 ≔ 𝑑2𝜔𝑐
2     𝑎𝑛𝑑 𝐸4 ≔ 𝑑1𝜔𝑐
3 − 𝑑3𝜔𝑐 
 
Now by solving equations (4.23) and (4.24) together we have  
𝑑𝛼
𝑑𝜏




2                                                               (4.25) 
 




















                                                                 (4.27) 
Finally, we incorporate equations (4.26) and (4.27) into equation (4.25) and obtains  
𝑑𝛼
𝑑𝜏







2 ≠ 0                                                                                    (4.28) 
Consequently we conclude based on equations (4.26), (4.27) and (4.28), the existence 
of Hopf bifurcation when, 𝜏 passes through the critical value 𝜏𝑐 
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4.6    PROOF FOR THE EXISTENCE OF HOPF BIFURICATION 
In this section we prove for the existence of Hopf Bifurcation by assuming that 
𝑎1, 𝑎2, 𝑎5 > 0  𝑎𝑛𝑑 𝑎3 > 1, 𝑓𝑜𝑟 𝜏𝑐 𝑎𝑛𝑑 𝜔𝑐 as defined in equation (4.14). Therefore by 
lemma 4.2 (i) if 𝑝 ≥ 0, 𝑞 ≥ 0, then we conclude that the system of delay differential 
equations proposed in equation (4.2) for the whole delay process has Hopf bifurcation. 




0. This is further supported by lemma 4.1 and theorem 4.1. The forward bifurcation 
analysis is portrayed by figure 4.1, where 𝜏 = 𝑞𝜔𝑐,  𝜔𝑐 = 0.024, 𝑃 = 1000, 𝑞 = 2200 ,
𝐸1 = 0.029 and 𝐸2 = 0.06. The conditions for the existence of Hopf bifurcation have 
been extrapolated by the above analysis. Hence, figure 4.1 portrays the conditions for 
the model to have a forward bifurcation under a single endemic equilibrium. 
 
Figure 4.1: Demonstration of the forward bifurcation process of the model with 𝜏 against 
𝜏𝑐: where 𝜏𝑐 = 𝑞𝜔𝑐,  𝜔𝑐 = 0.024, 𝑃 = 1000, 𝑞 = 2200 , 𝐸1 = 0.029 and 𝐸2 = 0.06. 
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4.7     NUMERICAL SIMULATION 
The numerical simulations are engaging around the convergence of orbits of the global 
stability and the presence of Hopf bifurcation for the system (4.28). The results are 
enjoined to flaunt the effects of intracellular delay on the affirmative behavior of the 
three variables: CD4+T-cell, symbolized (x), cells tainted with HIV, symbolized (y) and 
CTL, symbolized (z). 
The numerical simulations are wielded on the variables to corroborate the theoretical 
anticipations deliberated in chapters 2, 3 and 4. The values of the parameters such 
𝑎1, 𝑎2, 𝑎3, 𝑎4, 𝑎5, were used as seen from the above propositions and equations in 
chapter four to corroborate a pragmatic biological simulation of the results. The 
numerical results of the system of equations as per chapters 2, 3 and 4 were solved 
numerically as per the sixth order Runge –Kutta method with parametric values from 
𝑎1, 𝑎2, 𝑎3, 𝑎4 𝑎𝑛𝑑 𝑎5. 
Firstly, the model was analyzed without the delay component embedded (only ODE), 
under the following conditions: justification of the qualitative conduct of the three 
variables such as CD4+T-cell(x), HIV(y), and CTL(z) and controlling the fundamental 
reproductive rate of the virus. This was made possible through numerical simulations to 
vouch the theoretical conjecture stipulated in chapters 2, 3 and 4. When intracellular 
delay was overlooked and the fundamental reproductive number was under control, 
equation 2.2 was solved numerically as per the 6th order Runge-Kutta strategy with 
𝑎1 = 0.224 , 𝑎2 = 0.941, 𝑎3 = 0.369, 𝑎4 = 4.651, 𝑎5 = 1.311.  
Figure 4.2 (appendix A.1), portrays the numerical simulation of the quantum of CD4+T-
cells, HIV virus and CTL in the blood discretely. CD4+T-cell were consistent over time, 
whilst the quantum of CTL and the virus in the blood approaches zero. Figure 4.2d 
(appendix A.1) centers on the compactness of HIV and CTL in the blood, as they 
approaches the vanishing stretch to confirm the connection amidst the virus and the 
immune response  
Hence, the numerical outcome represented in Figure 4.2 (appendix A.1) correlates with 
the theoretical conjectures anticipated in Proposition 4.2(i) and equation 2.2. Therefore 
when 𝑎3 < 1,  a steady state was attained at (1, 0, 0). This implies that the essential 
conceptive pace of the infection was under control level hence, the decline rate of viral 
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production is higher than the production rate. Consequently, the virus could not spread 
and it’s eliminated from the blood, when CD4+T-cell become consistent at 𝛿1/𝛿3 
 
On the contrary, when the model was analyzed with the embedment of the delay 
component (DDE), under the following conditions: justification of the qualitative conduct 
of the three variables such as CD4+T-cell(x), HIV(y), and CTL (z) and controlling the 
fundamental reproductive rate of the virus, equation 4.1 was solved numerically using 
the 6th order Runge-Kutta technique were 𝑎1 = 0.224,  𝑎2 = 0.941, 𝑎3 = 0.369,  𝑎4 =
4.651,  𝑎5 = 1.311 , 𝜏 = 0.191. Figure 4.3 (appendix A.2), portrays the quantum of 
CD4+T-cells, HIV virus and CTL in the blood discretely. The quantum of CD4+T-cell 
gets consistent over time, whilst CTL and the virus in the blood approaches zero. Figure 
4.3(d), (appendix A.2) centers around the conduct of the compactness of HIV and CTL 
as they approach the vanishing point, to confirm the connection amidst the virus and the 
immune response. Therefore, the numerical outcome represented in Figure 4.3(a, b, c) 
(appendix A.2), correlates with the theoretical conjecture anticipated in Proposition 4.2(i) 
and equation 4.1. Therefore when 𝑎3 < 1,  a steady state was attained at (1, 0, 0). This 
implies that the essential conceptive pace of the infection was under control level 
hence, the decline rate of viral production is higher than the production rate. 
Consequently, the virus could not spread and its eliminated from the blood, when 
CD4+T-cell become consistent at 𝛿1/𝛿3.  
The model with delay was more advantageous over the non-delay model, because it 
was more stable at the trajectory. It supports viral peak postponement and virological 
suppression better than the non-delay (figure 4.2 and 4.3). 
 
 
Another dimension to the analysis was the removal of the delay component under the 
following conditions:  justification of the qualitative conduct of the three variables such 
as CD4+T-cell(x), HIV(y), and CTL (z) and this time, not controlling the fundamental 
reproductive rate of the virus. When intracellular delay was overlooked and the 
fundamental reproductive number was on grip, equation 2.2 was solved numerically as 
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per the 6th order Runge-Kutta strategy with now 𝑎1 = 0.1038 , 𝑎2 = 3.22, 𝑎3 = 2.64,
𝑎4 = 7.41, 𝑎5 = 4.17.  
Figure 4.4c, (appendix A.3), portrays the quantum of CTL in the blood which 
congregates at a universal point. Figure 4.4(d) (appendix A.3) centers around the 
conduct of the compactness of HIV and CTL, as they approach the vanishing stretch to 
confirm the connection amidst the virus and the immune response.  
Therefore, the numerical outcome represented in Figure 4.4(a, b, c) (appendix A.3) 
correlates with the theoretical conjectures anticipated in Proposition 4.2(ii) and equation 
2.2. Hence, a steady state was attained at (0.83, 0.46, 0.46), when 𝑎3 > 1. This 
intimates that the essential conceptive pace of the infection is not under control hence, 
the decline rate of viral production is lower than the production rate. Infection rate 
emerges and more virions are produced in the blood. 
 
Contrary to the above, the model was further analyzed with the delay component 
(DDE), under the following conditions: justification of the qualitative conduct of the three 
variables such as CD4+T-cell(x), HIV(y), and CTL (z). The fundamental reproductive 
rate of the virus was uncontrolled and equation 4.1 was solved numerically using the 6th 
order Runge-Kutta technique with 𝑎1 = 0.1038, 𝑎2 = 3.22,  𝑎3 = 2.64, 𝑎4 = 7.41,  𝑎5 =
4.17 , 𝜏 = 0.19. Figure 4.5(a, b) (appendix A.4), portrays the quantum of CTL in the 
blood which congregate at a universal point. Figure 4.5(d) (appendix A.4) centers 
around the conduct of the compactness of HIV and CTL in the blood. The levels of CTL 
and HIV in the blood approach the vanishing stretch, to confirm the connection amidst 
the virus and the immune response. 
  
Therefore, the numerical outcome represented in Figure 4.5(appendix A.4) correlates 
with the conditions of proposition 4.2 (i) and equation 4.1. Hence, when 𝑎3 > 1 𝑎𝑛𝑑 𝜏 <
𝜏𝑐, a constant steady state of (0.83, 0.46, 0.46) was attained. This intimates that the 
essential conceptive pace of the infection was not under control hence, declining the 
rate of viral production. Infection rate emerges and more virions are produced in the 




4.8    STRUCTURED TREATMENT INTERRUPTION 
The quest for legit structured treatment interruptions has necessitated the essence of 
intracellular delay in STI models. Currently, the adopted STI used by many HIV 
individuals does not incorporate days-off for drug assimilation by the body. Arguably 
therapy interruptions should align across days and weeks, in order to allow for drug 




4.8.1   TWO-WEEKS-ON TWO-WEEKS-OFF STRATEGY (14/14) 
The scenario above relates to 14 days on treatment and 14 days off regime therapy, 
designed for HIV patients. However, adherence to the regime yields an auto viral control 
compared to the primitive STI system [24, 25, 128], which aligns with lengthy periods of 
therapy. In reference to Fig. 4.8, this strategy yields a momentous average viral load of 
586virions/ml and 3371virions/ml at peak level. On the contrary, a continuous therapy 
without any interruption increases the viral haul to 633virions/ml on the average. This 
implies that the shorter the period for a particular therapy, the lower the peak viral haul. 
Therefore the lower the peak viral haul, the less the augmentation of viral strains, 




Figure 4.8:  Graphs of STI which shows 14 days on and 14days off: 
 
 Figure 4.8 (a), shows a therapy of 14 days on treatment and 14 days off therapy. It 
reveals an average viral haul of 8446virions/ml with zero delay and 586virions/ml for a 
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24hr delay. In addition to the average viral haul, the peak viral hauls were 
5837virions/ml and 3371virions/ml respectively.  
 
Again, figure 4.8 (b), reveals that a ceaseless therapy permits a 50% cost saving, 
because it limits the replication of target cells and allow them to uphold feasible levels. 
Hence, a ceaseless therapy has the tendency of migrating high viral haul of 
5837virions/ml, which is an epitome for the development of drug resistant mutations 
(DRMs). Therefore, with reference to the ongoing discussion, a short cycle therapy is 




4.8.2   FIVE-DAYS-ON TWO-DAYS-OFF STRATEGY (5/2) 
The five days on and two days off STI strategy allows treatment from Monday to Friday, 
with Saturday and Sunday as weekends off treatment. This strategy, also inferred as 
weekend off strategy is vital in subduing long term viral replication [43, 61, 101]. It 
enhances a decrease in drug residual level, since its squatty intermission period allows 
for the assimilation of DRM.  Hence in curbing down monotherapy situations, the usage 
of particular drugs should be disengaged for suitable metabolism rate.  
 
In addition, the five days on and two days off regime, supports a decline of the 
maximum viral haul. It is worth to note that escalations in viral haul have been a 
headache for most scientists. Therefore knowledge about the peak viral haul is crucial 
and personifies a larger viral pool which begets mutations. Based on the 5/2 strategy a 
cost saving of 29% is marginalized, as compared to the continual therapy. In addition, 
the 5/2 strategy produces low viral haul due to limited viral rebound. Furthermore, the 
strategy is useful to places where therapy is not consistent and hence reliable to stop 
therapy for two days, than to abort the whole process due to limited drug availability. In 
accordance with the above discussions, the 5/2 strategy appears to be reasonably 




Figure 4.9:  Demonstration of 5 days on and 2 days off therapy 
 
 From figure 4.9, the 5 days on and two days off therapy induces a mean viral haul of 




4.8.3   IMPACT OF VARYING THE ON AND OFF PERIOD 
The idea of varying treatment on and off has conceited imperative due to less access to 
ARV, cost concerns and ceaseless treatment. However off-treatment should not be 
prolonged due to high viral rebound and viral mutation to drugs. 
 
This section contrasts the 5/2 system, the 20/8 system and the 26/2 system and 
suggest the way forward. The ceaseless treatment period was used as reference and 
therapy was tempered as per the three systems above (Figure 4.10). It was observed 
that tempering with therapy for a short period of time was essential due to the following 
reasons: accessibility to ARV, cost concerns and discontinuity of therapy due to ARV 
shortage. Therefore the shorter the time frames for off treatment, the better the results 
and the lesser the viral rebound [107, 109, 128]. 
 
In accordance with the ongoing analysis, it was ascertained that the 26/2 system (table 
4.1) stimulates a reliable outcome, however the system is not decisive due to its little 
cost sparing of about 7%. On the other side, the 20/8 system appears to have a lower 
viral haul than the 5/2 system. The respective average and peak viral hauls for the 20/8 
system were 352virions/ml and 751virions/ml respectively. The 5/2 system also 
articulated 437virions/ml and 756virions/ml respectively. In view of the above outcome a 
trade- off is simulated to enhance the choice and adoption of a suitable treatment 
interruption (figure 4.10). Therefore the next section enhances the selection of the 












Figure 4.10:  Correlation of the 5/2, 20/8 and 26/2 STI Regime 
 
 
The average viral haul as per the 5/2, 20/8 and 26/2 discretely were 437virions/ml, 
352virions/ml and 70virions/ml respectively. On the other hand the peak viral hauls 
stands at 756virions/ml, 751virions/ml and 138virions/ml respectively.  
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4.8.4   OVERALL STI REGIME COMPARISON 
The above examination has conceited essential in adjusting treatment on and off, 
thereby diminishing the pinnacle viral haul. The 18/3 and 24/4 systems enhances a 
minimum viral haul of 120 and 118virions/ml respectively and a peak viral haul of 285 
and 338virions/ml respectively (Table. 4.1). In accordance with the above analysis, the 
18/3 system permits a 14% decrease in the total cost of treatment whilst subduing the 
control of HIV replication. Further the 18/3 and 24/4 systems articulates an additional 
time for ARV to be cleared from the body, compared to the 12/2 system and other 
systems discussed above.  Moreover, it is worth to articulate that the accumulation of 
treatment period brings about viral escalation. Hence the 24/4 system and the 18/3 
system, adheres to both week by week and month to month cycle, whist keeping the 
viral haul at low levels. Additionally, the systems keep up key cell levels, important to 
permit the human resistive system to ward off shrewd diseases.  
Therefore, based on the above analysis the 18/3 and 24/4 systems have been 
recommended for compliance and adoption due to low viral haul production (figure 
4.11). The 18/3 system produces an average and peak virions of 120 and 285virions/ml 










Figure 4.11:  Comparison of the STI systems; (24/4, 21/3, 12/2) 
  
From the graph above, the 24 days on treatment and 4 days off treatment was found to 







Mean Viral haul 
Virions/ml 
highest Viral haul 
Virions/ml 
% Cost Saving 
5/2 437 756 29 
12/2 126 320 14 
11/3 209 623 21 
19/2 86 171 10 
18/3 120 285 14 
17/4 168 465 19 
16/5 235 751 24 
26/2 70 138 7 
25/3 92 218 11 
24/4 118 338 14 
23/5 151 507 18 
22/6 201 743 21 
21/7 558 1086 25 
30/5 114 408 14 
36/6 121 495 14 
42/7 117 610 14 
 
Table 4.1: Demonstration of treatment strategies, viral load level and corresponding 
cost 
The table shows the average viral haul, peak viral haul and cost savings, relevant for 




4.8.5    SUMMARY OF STRUCTURED TREATMENT INTERRUPTIONS 
This area has specifically dealt with the various treatment systems and the system 
which supports the adopted model for compliance. The systems have featured on the 
significance of time on- and –off therapy and how to meliorate life expectancy under HIV 
[11]. However, the 18 days on treatment and 3 days off treatment was recommended as 
a suitable tradeoff between viral concealment and cost sparing. It allows the cells of the 
body 3 days’ rest, to incorporate the assimilated drugs. Therefore the 18/3 system is 
likewise suggested for utilization, for circumstances where accessibility for treatment 
isn't predictable. 
Further, the 24/4 system of treatment is  proposed as well, due to its adherence to 

























CONCLUSION AND FUTURE DIRECTIONS 
 
5.0    INTRODUCTION 
This chapter is interconnected with the general overview of the study and the summary 
of findings. The chapter is further interlocked with future directions to researchers and 
the conclusion of the study. 
 
 
5.1    GENERAL OVERVIEW 
In HIV tainted people, the disease displays an extended unidentifiable stage, 
realistically around 10 years before the beginning of AIDS. During this brooding space 
which is the clinical inactivity time frame, the person seems, by all account to be 
credible and may contribute fundamentally to the propagation of the virus within a 
locality. Some clinical attributes, for example, CD4 cell count and RNA viral haul 
(viraemia), are some of the indicators which articulate clues about the buildup of the 
disease [159]. Likewise, the clinical idleness time supports the ailment to escalate 
unobtrusively.  
 
Arguably, the conception of medication was triggered by the pathogenesis of the virus, 
which embodies the strapping of the virus to gp120 protein on the CD4 cell, the 
passage of the viral RNA into the objective cell, the opposite exchange of viral RNA to 
viral DNA and the mixing of the viral DNA with the host cell. In an attempt to inhibit the 
replication of the virus, scientist has developed drugs such as AZT and Ritonavir, 
among others to combat or inhibit the spread of the virus. The drugs are meant to inhibit 
the reverse transcriptase and the protease transcriptase of the virus. The reverse and 
the protease inhibitors diminishes the creation of the virus and hence deferred the onset 
of AIDS [16, 150, 157]  
A remedy for HIV is yet to be found, however progress is being made in acquiring 
powerful vaccines for destroying the infection from the human body. For instance, as of 
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late a bone marrow transplant of an HIV tainted individual suffering from leukemia, was 
auspicious with no traits of the virus in his framework (the blood and the reservoirs were 
not tainted with the virus). Based on this successful bone marrow transplant, one could 
retort that the redress to HIV/AIDS is within reach. However this redress is not 
dependable, due to its extravagant nature and requires a lot of investment form the 
tainted individual. Again, it requires the passage of time for the tainted individual to 
advance in immunity, since a quantum of time is needed for the new stem cells to 
advance and duplicate (http://www.welt.de/english-news/article2715739/HIV-patient-
curedby-marrow transplant.html). 
Further, it worth to articulate that, with the boundless nature of the pandemic and a 
redress not in sight, it is worthwhile to rely on remedial and therapeutic mediation [29, 
30, 133, 134] 
 
Notwithstanding, in the past and even recently several researches are ongoing to 
explore the repercussions of therapy on HIV tainted people. [121,152,153,154]. Hence, 
researchers have resulted to remediation [100, 165], which has the capacity to defer the 
onset of AIDS through defective interfering virus (DIVs). DIVs meddle with the 
replication of the virus [152, 153]. Hence, it is a cancellation mutant which is 
unequipped for duplication without a host cell (CD4 cell), but reproduces when the host 
cell is contaminated with HIV. 
 
Noting that DIV relies on HIV to increase, a scientific model [39, 40] was developed to 
imbibe HIV, DIV and uninfected CD4+Tcells. A compartmental approach was used to 
confine DIV and HIV in a solitary cubicle. This was followed by an arrangement for 
normal differential conditions, including eight factors and a few parameters relating to 
DIV and HIV. Further, a more significant degree of DIV was created to consist of 
contaminated CD4+Tcells, which was used as a hindrance to the replication of the virus 
[39, 40] 
 
Notwithstanding, the aftermath of several investigations on HIV replication were 
examined [29, 30, 49, 50, 51] and the remarks was that, the virus has a tremendous 
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potentials in demonstrating a high impedance against HIV drugs. Further, it was 
discovered that [112] the virus has a high drug opposition and a remarkable mix of 
change in individuals, when a stochastic model was proposed to test the impact of 
protease inhibitors. Again through numerical approach [63, 100] the dynamic image of 
HIV pathogenesis was utilized, to ascertain how Ritonavir could repress strongly against 
the virus. In relation to finding a drug which could suppress HIV [100, 101], elements of 
cell contamination and viral creation after the administration of ritonavir were 
considered. Hence ordinary differential equation was used to infer a 100% inhibition by 
the drug. Therefore by utilizing the numerical model and non-direct least squares fitting 
of the viral burden of five people, the projection of the viral clearance rate, cell duration 
and viral procreation time were ascertained [137]. 
 
In addition, a discovery on the evolution of HIV, based on a universal-space model was 
accustomed. Hence HIV tainted people, experiencing a blend of treatment, with a mix of 
antiviral medications (AZT and Ritonavir), were used to restrain the reverse 
transcriptase or the protease transcriptase [83]. The model flourished on the creation of 
irresistible free and noncontagious free HIV. This was achievable through the creation 
of methodology which assesses and anticipates the quantity of untainted CD4+Tcells, 
irresistible free HIV, non-irresistible free HIV and HIV tainted CD4+Tcells.  
 
Per the achievement of Tan and Xiang, not only did they broaden Perelson et al’s model 
into a stochastic model, but additionally applied the model stochastically to HIV tainted 
individuals [143, 144]. They developed a discrete time model which was depicted by an 
arrangement of stochastic contrast conditions, inferred on the organic details of HIV 
replication.  
Nonetheless it’s worth articulating that the HIV virus has the propensity to unfold at a 
faster rate, about 1 million times faster than the human DNA. This hallmark of the virus 
is advantageous in evolving over antiviral treatments and sometimes replicating 
unnoticed.  
This high replicative ability of the virus renders drugs ineffective, hence the luxury of this 
study in using delay differential equation to model low HIV viral haul. The model is 
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further extended to explore the effects of structured treatment interruptions and 
adoption of the best STI regime for compliance.  
 
 
5.2    SUMMARY OF FINDINGS 
The aim of the paper is to unveil the niche of delay differential equation in harmonizing 
low level HIV viral haul and thereby articulating the adopted model to delve into 
structured treatment interruptions.  
 Hence, the sturdiness of the model with delay (equation 4.1) and without delay 
(equation 2.2) was assessed. Numerical simulations were used to consolidate the 
results. 
The demands for the stability of Hopf bifurcation [12] was authenticated in itemizing the 
initial conditions of the model (figure 4.1). The existence of Hopf bifurcation [12, 137] 
has been proved and hence occurs when, 𝜏 passes through the critical value 𝜏𝑐. 
 
 Firstly, the model was analyzed without the delay component embedded (only ODE), 
under the following conditions: justification of the qualitative conduct of the three 
variables such as CD4+T-cell(x), HIV(y), and CTL(z) and controlling the fundamental 
reproductive rate of the virus. This was made possible through numerical simulations to 
vouch the theoretical conjectures stipulated in chapters 2, 3 and 4. When intracellular 
delay was overlooked and the fundamental reproductive number was under control, 
equation 2.2 was solved numerically as per the 6th order Runge-Kutta strategy with 
𝑎1 = 0.224 , 𝑎2 = 0.941, 𝑎3 = 0.369, 𝑎4 = 4.651, 𝑎5 = 1.311.  
Figure 4.2 (appendix A.1), portrays the quantum of CD4+T-cells, HIV virus and CTL in 
the blood discretely. CD4+T-cell become consistent over time, whilst the quantum of 
CTL and the virus in the blood approaches zero. Figure 4.2d (appendix A.1) centers on 
the compactness of HIV and CTL in the blood, as they approaches the vanishing stretch 
to confirm the connection amidst the virus and the immune response  
Hence, the numerical outcome represented in Figure 4.2 (appendix A.1) correlates with 
the theoretical conjectures anticipated in Proposition 4.2(i) and equation 2.2. Therefore 
when 𝑎3 < 1,  a steady state was attained at (1, 0, 0). This implies that the essential 
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conceptive pace of the infection was under control level hence, the decline rate of viral 
production is higher than the production rate. Consequently, the virus could not spread 
and it’s eliminated from the blood, when CD4+T-cell become consistent at 𝛿1/𝛿3 
 
On the contrary, when the model was analyzed with the embedment of the delay 
component (DDE), under the following conditions: justification of the qualitative conduct 
of the three variables such as CD4+T-cell(x), HIV(y), and CTL (z) and controlling the 
fundamental reproductive rate of the virus, equation 4.1 was solved numerically using 
the 6th order Runge-Kutta technique were 𝑎1 = 0.224,  𝑎2 = 0.941, 𝑎3 = 0.369,  𝑎4 =
4.651,  𝑎5 = 1.311 , 𝜏 = 0.191. Figure 4.3 (appendix A.2), portrays the time series plot of 
the quantum of CD4+T-cells, HIV virus and CTL in the blood discretely. The quantum of 
CD4+Tcell gets consistent over time, whilst CTL and the virus in the blood approaches 
zero. Figure 4.3(d), (appendix A.2) centers around the conduct of the compactness of 
HIV and CTL as they approach the vanishing point, to confirm the connection amidst the 
virus and the immune response. Therefore, the numerical outcome represented in 
Figure 4.3(a, b, c) (appendix A.2), correlates with the theoretical conjecture anticipated 
in Proposition 4.2(i) and equation 4.1. Therefore when 𝑎3 < 1,  a steady state was 
attained at (1, 0, 0). This implies that the essential conceptive pace of the infection was 
under control level, hence the decline rate of viral production is higher than the 
production rate. Consequently, the virus could not spread and its eliminated from the 
blood, when CD4+T-cell become consistent at 𝛿1/𝛿3.  
The model with delay was more advantageous over the non-delay model, because it 
was more stable at the trajectory. It supports viral peak postponement and virological 
suppression better than the non-delay (figure 4.2 and 4.3). 
 
 
Another dimension to the analysis was the removal of the delay component under the 
following conditions:  justification of the qualitative conduct of the three variables such 
as CD4+T-cell(x), HIV(y), and CTL (z) and this time, not controlling the fundamental 
reproductive rate of the virus. When intracellular delay was overlooked and the 
fundamental reproductive number was on grip, equation 2.2 was solved numerically as 
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per the 6th order Runge-Kutta strategy with now 𝑎1 = 0.1038 , 𝑎2 = 3.22, 𝑎3 = 2.64,
𝑎4 = 7.41, 𝑎5 = 4.17.  
Figure 4.4c, (appendix A.3), portrays the quantum of CTL in the blood which 
congregates at a universal ‘point. Figure 4.4(d) (appendix A.3) centers around the 
conduct of the compactness of HIV and CTL, as they approach the vanishing stretch to 
confirm the connection amidst the virus and the immune response.  
Therefore, the numerical outcome represented in Figure 4.4(a, b, c) (appendix A.3) 
correlates with the theoretical conjectures anticipated in Proposition 4.2(ii) and equation 
2.2. Hence, a steady state was attained at (0.83, 0.46, 0.46), when 𝑎3 > 1. This 
intimates that the essential conceptive pace of the infection is not under control hence, 
the decline rate of viral production is lower than the production rate. Infection rate 
emerges and more virions are produced in the blood. 
 
Contrary to the above, the model was further analyzed with the delay component 
(DDE), under the following conditions: justification of the qualitative conduct of the three 
variables such as CD4+T-cell(x), HIV(y), and CTL (z). The fundamental reproductive 
rate of the virus was uncontrolled and equation 4.1 was solved numerically using the 6th 
order Runge-Kutta technique with 𝑎1 = 0.1038, 𝑎2 = 3.22,  𝑎3 = 2.64, 𝑎4 = 7.41,  𝑎5 =
4.17 , 𝜏 = 0.19. Figure 4.5(a, b) (appendix A.4), portrays the quantum of CTL in the 
blood which congregate at a universal point. Figure 4.5(d) (appendix A.4) centers 
around the conduct of the compactness of HIV and CTL in the blood. The level of CTL 
and HIV in the blood approaches the vanishing stretch, to confirm the connection amidst 
the virus and the immune response. 
  
Therefore, the numerical outcome represented in Figure 4.5(appendix A.4) correlates 
with the conditions of proposition 4.2 (ii) and equation 4.1. Hence, when 𝑎3 > 1 𝑎𝑛𝑑 𝜏 <
𝜏𝑐, a constant steady state of (0.83, 0.46, 0.46) was attained. This intimates that the 
essential conceptive pace of the infection was not under control, hence declining the 
rate of viral production. Infection rate emerges and more virions are produced in the 
blood. The elongation of the infection leads to the inception of AID (Figure 4.5) 
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In relation to the conditions imposed on the adopted model, a validation of the model is 
ascertained by relating it to potential treatment strategies for compliance. The adopted 
STI under consideration is significant due to limited ARV accessibility. It is also worth at 
asset restricted areas. Hence, such areas do not have consistent access to treatment 
and could lead to the escalation of the virus. A typical example is the restricted 
medication accessibility and sometimes shortage of TB vaccines.  
 
In lieu of the various treatment strategies considered, the 24 days on treatment and 4 
days off- treatment were found to be reliable. 24/4 system created a cost sparing of 
14%, when contrasted with the continual therapy treatment. It is essential to note that 
the 4 days off therapy, allows the body some time to assimilate the medication without 
essentially influencing viral concealment. This is highly applicable in places or locations 
were ART is constrained. Refreshingly, it is smarter to stop treatment for a short period 
of time, instead of abandoning the whole process due to shortage of medication. This 
suspension lessens the possibility of curtailing drug resistance mutation, which may 




5.3    FUTURE DIRECTIONS 
The DDE model created here depends on the ODE model, which was upgraded with 
the delay component to ascertain the viral haul of an individual. The embedment of 
intracellular delay depends on the time interval relevant for the body to produce virions.  
However, the developed DDE model is authenticated through the recommended STI 
systems. The STI systems were developed based on strict ethical human data. 
Therefore, the verification of the recommended STI system is a gate way for future 
research and adoption [137].  
 
Again several works have been done in this area which includes ODE modelling, 
optimal control and open-loop control [1137,165,], besides most of these models came 
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short of the addition of intracellular component, which appears to diminish viral haul, 
hence an exciting area for further research. 
 
Notwithstanding, due to increased imposition on treatment interruptions the study 
recommends for the application of controlled techniques to enhance the adopted model. 
 
Finally, the use of optimal control with distributed delay could also be exploited due to 




5.4     CONCLUSION 
In reference to the aim of the study, the sturdiness of the model with delay (equation 
4.1) and without delay (equation 2.2) was assessed. Numerical simulations were used 
to consolidate the results. 
The demands for the stability of Hopf bifurcation were authenticated in itemizing the 
initial conditions of the model (figure 4.1). The existence of Hopf bifurcation [12,137] has 
been proved and hence occurs when, 𝜏 passes through the critical value 𝜏𝑐. 
 
The analysis of the results indicated that when the basic reproductive rate of the virus 
was under control and the delay component 𝜏 were embedded in the model to verify the 
qualitative behavior of the three variables, such CD4+Tcells (x), HIV cells (y) and CTL 
(z). It was concluded that when 𝑎3 < 1, then by proposition 4.2(i): a steady state exists 
at (1,0, 0). Therefore the pace of infection of the virus is under control and the decline 
rate of viral production is higher than the production rate at 𝛿1/𝛿3 
Conversely when 𝑎3 > 1, then as per proposition 4.2(ii) : a non-existence steady state 
occurs. Therefore the pace of the contagion is higher than the decline rate at 𝛿1/𝛿3 and 
AIDS intercepts. [1, 16] 
Adherence to the conditions imposed on proposition 4.2(i) when 𝑎3 < 1, intimates that 
the reproductive ratio of the virus is under control. This signifies a stable CD4+ T cells, 
hence adherence to therapy could delay AIDS interception. Further, by the conditions of 
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proposition 4.2(i) we have revealed an abortive attempt by the virus, due to the 
consistent increase in CD4+ T cells (figure 4,4). Hence, CTL consequently eliminates 
the virus from the body. This is made possible when CD4+ T cells converges at    𝛿1/𝛿3 
 
Again sustenance of the imposed conditions on proposition 4.2(i), is central to 
virological suppression and increased life expectancy under HIV [122, 141, 152]. 
Therefore it is imperative to ascertain the time frame, for the adaptive immune response 
of the body to emerge in regulating viral replication. This is supported when 𝑎3 < 1 .  
 
Further, from the above deductions, patients with strong CTL and CD4+T cells will have 
a higher stable state and low viral contagion. This indicates that patients with low CTL 
and CD4+T cells will demonstrate a higher rate of viral infection. 
 
Consequently when the emanation of delay from latent cells is kept extremely low, then 
the immune reaction could be kept at a significant level. However the concepts of 
suppressing viral particle from emanating to larger quantities are relevant in the 
manufacture of drugs. The administration of drugs to HIV tainted individuals are made 
effective through the STI systems, which were discussed in detailed in chapter four. 
 
Referencing the challenges associated with HIV tainted individuals seeking for 
treatment and the need to maximize the benefits accruing from treatment, requires a 
suitable STI system. This study articulates structured treatment interference as a 
potential method for accomplishing low treatment cost whilst, keeping up with fruitful 
treatment options, especially in asset restricted areas. Interestingly, past 
disappointment on the usage of the traditional treatment options, has necessitated the 
use of STI for better suppression of the infection level. [133,134] 
 
It’s imperative to insinuate that the treatment interference models recommended by this 
study requires a short period off medication, meaning that treatment should just be 
expelled for some few days to allow for drug assimilation. The short interference period 
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demonstrates how unfruitful longer-term interference systems, have been over the 
years and hence the need for future alternatives. 
 
Further, in compliance with the rigorous analysis imposed on treatment options, the 
study hereby recommends for a short period off medication. This certifies that treatment 
should be expelled for only few days to allow for drug assimilation [68]. Therefore In 
reference to the imposed interactions on STI systems, the study recommends for the 24 
days on treatment and 4 days off treatment for compliance. 18 days on treatment and 3 
days off treatment is also supported by the study. [8, 12] 
 
Finally, it is further suggested that due to increase in treatment imposition, the 
recommended STI models (24 days on treatment and 4 days off treatment: 18 days on 
treatment and 3 days off treatment) could be made more potent and viable when 
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Figure 4.2 (a, b, c, d) shows the Numerical simulation of the model without the delay 
component. 
Figure 4.2(a) shows how the quantum of CD4+T-cells approaches zero, while 4.2(b) 
and 4,2(c) shows the amount of HIV and CTL in the blood respectively Figure 4.2(d) 











Figure 4.3(a, b, c, d) shows the Numerical simulation of the model with the delay 
component system.  
Figure 4.3(a) shows how the quantum of CD4+T-cells approaches a constant value 
whilst 4.3(b) and 4.3(c) shows how the quantum of HIV decreases whilst CTL remains 
constant over time. 
Figure 4.3(d) shows how the virus component decreases over time as CTL in the blood 







Figure 4.4(a, b, c, d): shows the numerical simulation of the model without the delay 
component and the reproductive number is not constant 
Figure 4.4(a), the quantum of CD4+T cells approaches a constant value: 4.4(b) and 
4.4(c) shows how HIV and CTL component in the blood fluctuates before assuming a 
common point, with time 











Figure 4.5(a, b, c, d) shows the numerical simulation of the model with delay whilst the 
reproductive number is not constant. 
Figure 4.5(a) shows how the quantum of CD4+T cells decreases over time and assume 
a constant value: Figure 4.5(b) and 4.5(c) shows fluctuations of HIV and CTL in the 
blood. The Virus has reached an uncontrollable state as CTL decreases    
Figure 4.5(d) shows an escalation of the virus component whilst CTL diminishes 










































(𝒎𝒍 × 𝟏𝟎−𝟑) 
1 70 181 
2 110 50 
3 210 80 
4 162 112 
5 257 76 
6 300 163 
7 373 171 
8 95 117 
9 215 90 
10 152 42 
11 107 113 
12 36 223 
13 32 19 
14 91 82 
15 342 173 
 
 










Variable Category % Frequency 
Outcome of patients Completed 180(70.3%) 
 Lost follow up 76(26.9%) 
   
Gender Female 108(60%) 
 Male 77(40%) 
   
Age ≤ 25 8(4%) 
 26-31 20(11%) 
 32-37 52(29%) 
 38-43 4(27%) 
 44-49 28(16% 
 ≥ 50 24(13) 
 
Table 4.3 Percentage viral load level after ARV administration 
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